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The inevitable progression of advanced prostate cancer to castration resistance, 
and ultimately to lethal metastatic disease, depends on primary or acquired resistance to 
conventional androgen-deprivation therapy (ADT) and accumulated resistance 
mechanisms to evade androgen receptor (AR) suppression. Whereas the canonical 
androgen/AR signaling axis maintains prostate cell growth, differentiation and survival, 
in prostate cancer cells, AR adaptations that arise in response to ADT are not singular, 
but diverse, and include gene amplification, mutation and even complete loss of receptor 
expression. Collectively, each of these AR adaptations contributes to a complex, 
heterogenous, ADT-resistant tumor that culminates in prostate tumor cells transitioning 
from epithelial to mesenchymal states (EMT) and the development of metastatic 
castration-resistant prostate cancer (mCRPC). Here, we examined prostate cancer cell 
lines that model common CRPC subtypes, each with different AR composition, and 
focused on novel regulators of tumor progression, the Bromodomain and ExtraTerminal 
(BET – BRD2, BRD3 and BRD4) family of proteins, to test the hypothesis that each BET 
family member regulates EMT and underlying characteristics such as cell motility and 
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invasiveness. We systematically manipulated the BET proteins and found that BRD4 
regulates cell migration and invasion across all models of CRPC, regardless of 
aggressiveness and AR status, whereas BRD2 and BRD3 only regulate cell migration and 
invasion in less aggressive models that retain AR expression or signaling. We determined 
that BRD4’s contribution to this process occurs through the transcriptional regulation of 
AHNAK, SNAI1 and SNAI2, which are EMT genes linked to promotion of metastasis in a 
diverse set of cancers. Furthermore, treatment of CRPC cell lines with low doses of MZ1, 
a small-molecule, BRD4-selective degrader, inhibits EMT and metastatic potential. 
Overall, these results reveal a novel, BRD4-regulated EMT gene signature that may be 
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PROSTATE CANCER HISTORICAL PERSPECTIVE  
 In 1853, surgeon J. Adams reported the first modern case of prostate cancer after 
making the discovery by histological examination (1). What was then described as a very 
rare disease, prostate cancer is now the most common cancer diagnosed in men in the 
United States, with over 170,000 new cases and over 31,000 deaths occurring annually 
(2). Although the rate of incidence for prostate cancer still increases more rapidly with 
age than any other cancer (2), a number of landmark discoveries over the past century 
have provided remarkable changes in diagnoses, treatments and outcomes. Between the 
time J. Adams reported the first prostate cancer case and the early twentieth century, 
multiple studies began to associate the size of the prostate to the size of the testes and 
secondary sex organs (1,3). In 1935, a report out of Yale University demonstrated that the 
removal of the testes by surgical castration reduced the size and weight of the prostate in 
primates (3,4). While it was unclear at the time as to the mechanism of action and 
ineffective in follow up studies to treat benign prostatic hyperplasia in humans (1,3,4), 
the potential for castration therapy was soon realized.  
By the end of the 1930’s, it was becoming evident that hormone production and 
prostate cancer progression were intimately linked (5). Then, in 1940, Dr. Charles 
Huggins developed the first method for measuring the effect of different hormonal 
manipulations on prostatic function (6). In this study, he discovered that the prostate 
glandular atrophy that resulted from castration could be reversed by reintroducing the 
androgen hormone (6,7). While this landmark study was the first to demonstrate the 
effects of androgen ablation in relation to prostate size and function, it was not until the 
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following year that patients with advanced prostate cancer were treated by surgical 
castration (8). Through these groundbreaking discoveries, and as described in more detail 
in the next subchapters, it is now understood that the signaling events that occurs between 
androgens and the cognate androgen receptor (AR) serve as the primary driver for normal 
prostate growth and for the development and progression of prostate cancer (9-11). 
CANONICAL ANDROGEN RECEPTOR SIGNALING 
 The prostate is located just below the bladder and has a primary function of 
providing sperm with 
an alkaline fluid to aid 





(DHEA)), are 19 
carbon (C19) male sex 
hormones that initiate 
male sexual 
development and 
differentiation, and are 
produced in the testes 
and adrenal glands  
Figure 1.1.  Androgen receptor signaling. Testicular 
testosterone and adrenal DHEA are converted locally in the 
prostate into bioactive DHT by the enzyme 5α-reductase. 
Androgen binding to the AR induces a conformational change that 
leads to the dissociation of chaperone and heat shock proteins 
(HSP40, HSP90) and its subsequent interaction with coregulatory 
molecules and importin-α, which facilitate nuclear translocation of 
AR–ligand complexes. In the nucleus, the AR undergoes 
phosphorylation and dimerization, which permits chromatin 
binding to androgen-responsive elements (ARE) within androgen-




(11,12). As shown in Fig 1.1, under normal biological conditions, the production and 
action of testosterone through AR (a 110 kDa ligand-dependent transcription factor 
belonging to the steroid hormone group of nuclear receptors) begins when luteinizing 
hormone (LH) is released by the pituitary gland and binds with luteinizing hormone 
receptors (LH-R) in the testes (11,12). This reaction, which synthesizes testosterone from 
cholesterol, enables testosterone to enter prostate cells where it, or DHEA (produced in 
adrenal glands), is converted to dihydrotestosterone (DHT) by 5α reductase (13,14). As a 
potent, reduced metabolite of testosterone, DHT binds with high affinity to the ligand-
binding domain (LBD), one of the four distinct domains – N-terminal domain (NTD), 
DNA-binding domain (DBD), hinge region and LBD - on AR (15-18). The binding 
between DHT and AR displaces cytoskeletal heat shock proteins (HSP)-40, -70 and -90, 
from AR, initiating conformational changes to AR that exposes multiple ligand-
dependent nuclear localization signals (NLS) in the DBD and hinge region (19-21). As 
the N and C termini of AR interact, Filamin-A (FlnA), an AR coactivator already bound 
to the NLS in the hinge region, and Importin-α, bind to the NLS in the DBD and 
translocate AR from the cytoplasm to the nucleus (19,20). Once inside the nucleus, AR 
forms a homodimer, and through its DBD binds to specific recognition sequences known 
as androgen response elements (ARE) in the promoter regions of target genes (21-24). 
This coordinated process leads to the recruitment of many coregulatory proteins critical 
for transcription of prostate cell pro-growth and survival genes; it also serves as the 




ROLE OF AR IN PROSTATE CANCER DEVELOPMENT AND PROGRESSION  
 While the androgen/AR signaling axis maintains normal prostate cell growth, 
differentiation and survival, it also facilitates the activation of pro-proliferative and 
invasive programs that directly contribute to the development and maintenance of 
metastatic prostate cancer 
(25,26). As discovered 
through years of translative 
studies, some of the major 
roles for AR in promoting 
prometastatic events include: 
enhanced transcription and 
activation of chemokine 
ligands/receptors (27,28), 
deregulation of AR cofactors 
(29) and AR-dependent gene 
fusions (30). As highlighted in 
Fig 1.2, AR signaling has 
been shown to stimulate the 
activation of a variety of 
chemokine receptors, including CXCR4 and CX3CR1 (27,31). CXCR4 is a G-protein 
coupled receptor that is well understood to elicit multiple signaling cascades that promote 
cell migration and survival (32). In the context of prostate cancer development, AR 
Figure 1.2.  AR mediated CXCR4 signaling. Signal 
transduction pathways induced by CXCL12 binding to 
CXCR4. Binding of CXCL12 to CXCR4 leads to the 
activation of various signal transduction pathways, 
resulting in diverse biological responses, including cell 





signaling has been shown to induce the expression of CXCR4 by enhancing the 
transcriptional output of the transcription factor Kruppel-like factor 5 (KLF5) (27). 
Moreover, subsequent studies have highlighted the specific mechanisms by which 
CXCR4 promotes prostate cancer metastasis, including homing of prostate cancer cells to 
bone (33,34). Furthermore, AR signaling has also been shown to mediate the cleavage of 
fractalkine (CX3CL1), a membrane bound cytokine that, when bound to the chemokine 
receptor CX3CR1, stimulates cell migration and invasion (28).  
 In addition to AR directly stimulating a variety of pro-migratory and invasive 
chemokine signaling pathways, cofactors associated with the binding of AR to AREs 
have also been shown to enhance AR-driven metastasis (35). Genome-wide analysis of 
the AR cistrome (location of transcription factor binding sites/sites of active 
transcription) found a large overlap between AR and the FOXA family of transcription 
factors (36). FOXA proteins help define states of active/open chromatin, and in studies 
that explored their roles in mediating prostate cancer progression, it was found that 
FOXA1 assists in recruiting AR to promoter regions of genes critical for the cell cycle 
(24,37). In addition to FOXA1, BAF57 (subunit for chromatin remodeling proteins 
SWI/SNF) and Cyclin D1b (splice variant of the well characterized cell cycle regulator 
cyclin D1) have also been shown to mediate AR-dependent metastatic events (38,39). 
Through elevated expression, these cofactors hijack AR-mediated transcription and 
increase the expression of pro-metastatic genes (40,41). 
 Progression to metastatic disease has also been linked to AR-driven genetic fusion 
products. While few genetic aberrations have been associated with the development of 
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prostate cancer, chromosomal fusion events that occur between TMPRSS2 (ARE gene) 
and members of the oncogenic erythroblast transformation specific (ETS) family (ERG, 
ETV1, ETV4) are known to facilitate metastatic progression (42,43). While the precise 
mechanism for generating these products is unclear, studies have shown that AR 
signaling assists in their formation by bridging the TMPRSS2 and ERG locus to allow for 
DNA recombination (30,44). Multiple in vitro and in vivo studies have subsequently 
shown that the byproduct of this chromosomal fusion promotes a metastatic phenotype, 
evidenced by elevated SOX9 expression (transcription factor that maintains stem-like 
progenitor cells), and an increased capacity to invade in tumor cells harboring this event 
(45-47). With an abundance of data from these and other studies detailing the prominent 
role that AR signaling has in driving metastatic disease, it is no surprise that the gold 
standard for treating men with advanced prostate cancer focuses on suppressing the 
androgen/AR axis.  
PROSTATE CANCER CLINICAL SIGNIFICANCE AND THERAPIES  
While improvements to standardizing medical treatments over the last century 
have led to the advent of chemotherapy, radiation therapy and in the case of prostate 
cancer, radical prostatectomies (48), the primary method for treating advanced prostate 
cancer remains disruption of the androgen/AR axis. Ever since Huggins and Hodges first 
used androgen ablation therapy to treat advanced prostate cancer (6,8), multiple 
approaches, including LHRH agonists (49), steroidal anti-androgens (cyproterone) (50) 
and non-steroidal anti-androgens (flutamide and bicalutamide) (51), have been utilized. 
While each of these therapies target certain aspects of the androgen/AR axis, today's form 
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of androgen ablation, androgen deprivation therapy (ADT), works by inhibiting both the 
synthesis  of androgens (abiraterone) and its interaction with the AR (enzalutamide) 
(52,53). 
As highlighted in the flow diagram below in Fig. 1.3 (54), men diagnosed with 
localized prostate cancer typically receive either surgery (prostatectomy), radiation, or in 
most cases, receive no treatment and are actively surveilled (55). If, however, men show 
signs of progression through either elevated levels of the prostate specific antigen (PSA) 
(AR-target gene) or present with metastases, they are then given abiraterone and 
enzalutamide (52,53). Abiraterone is a selective inhibitor of cytochrome P (CYP) 17, a 
key enzyme in androgen synthesis that works by converting precursor metabolites into 
Figure 1.3.  Prostate cancer clinical states. Different stages of prostate cancer as 
proposed by the Prostate Cancer Working Group 3  and the management options available 





DHT (56). As androgen production is reduced, enzalutamide works to further diminish 
AR signaling by competitively binding to AR (53). The binding between enzalutamide 
and AR prevents the receptor from translocating to the nucleus and activating AREs (53). 
Although ADT in the form of abiraterone and enzalutamide is initially quite effective and 
remains the gold standard for treating advanced prostate cancer, men who progress 
beyond this stage and develop resistance or distant metastases are defined as having 
castration-resistant or metastatic castration-resistant prostate cancer (CRPC/mCRPC) 
(57). Men with mCRPC live on average for 2 to 4 years, and treatment at this stage 
typically includes chemotherapy (Docetaxel/Cabazitaxel) and immunotherapy 
(Sipuleucel-T/Pembrolizumab) (58,59). As described in the next subchapter, a variety of 
resistance mechanisms, a majority of which reactivate AR signaling despite sustained 
suppression, contribute to the development and progression of metastatic disease in 
prostate cancer patients. 
MECHANISMS OF RESISTANCE TOWARDS ADT 
Despite the fact that abiraterone and enzalutamide effectively target and suppress 
key components of the androgen/AR signaling axis, most patients with aggressive 
prostate cancer inevitably progress to a state of castration-resistance (57,60,61). This 
progression, which occurs as a result of accumulated resistance mechanisms, leads to 
mCRPC (57,62). mCRPC is a lethal form of prostate cancer, and over 90% of prostate 
cancer mortality is due to the development of metastasis (57,62). In general, prostate 
tumor cells acquire resistance to ADT through multiple mechanisms (25,63-65). These 
mechanisms include, but are not limited to: AR amplification or overexpression (66,67), 
 
 10 
constitutive AR activation via alternative splicing (68,69) and gain-of-function AR 
mutations (70,71). 
One of the earliest indicators that demonstrated that AR overexpression was 
critical for overcoming ADT came when studies examining the genomic landscape of 
tumors obtained from CRPC patients before and after treatment with ADT discovered 
that 30% to 50% of these patients harbored genomic amplification of the AR locus after 
treatment (67,72). By overexpressing AR, prostate tumor cells enter a state of AR 
hypersensitivity (64,73). This state enables prostate tumor cells to interact with the low 
levels of androgens that still exist when the patient is being treated with ADT, and as a 
result, AR-dependent pro-proliferative and migratory genes are transcriptionally 
reactivated (64,73).  
Another ADT resistance mechanism includes the production of AR splice variants 
(AR-Vs) (64). AR-Vs are constitutively active forms of the receptor and most often occur 
through the loss of the C-terminal LBD (69). The predominant variants include ARV1, 
ARV7 and ARV567, and each are able to continually engage AREs due to the fact that 
the target of enzalutamide is the LBD (74). Furthermore, it has also been shown that 
these variants regulate both AR-dependent and -independent genes, which suggests that 
they each have distinct transcriptional roles relative to the full-length receptor (69,74).  
  A third type of resistance mechanism that has been shown to increase AR activity 
involves point mutations in the AR gene (75). Occurring most often in the LBD of AR, 
and identified in almost 30% of CRPC patients in previous translational studies, these 
mutations confer enhanced activity to AR through the promiscuous binding of non-
 
 11 
androgenic steroids (progesterone, estradiol) (76). The mechanism of action for some of 
the most prominent mutations was discovered when in studies that used xenograft models 
derived from CRPC patients harboring either a T878A or F876L point mutation, it was 
shown that flutamide and bicalutamide could activate AR-mediated transcripts (77,78). 
Whereas the majority of acquired mechanisms reactivate AR signaling and 
upregulate AR-dependent pro-metastatic and survival genes (79), more recent data also 
suggest that sustained repression of AR signaling can result in the complete loss of AR 
expression (80). Consistent with this rationale, previous studies have demonstrated that 
some mCRPC tumors fail to express AR after undergoing ADT (81,82). While the 
majority of tumors examined in these studies presented with the typical adenocarcinoma 
histology, concern remains that long-term usage of ADT will lead to increased incidence 
of neuroendocrine tumors through enhanced clonal selection of AR-null prostate cancer 
cells (65,80). 
Lastly, newer evidence also suggests that ADT enriches prostate cancer cells to 
undergo the epithelial to mesenchymal transition (EMT) (62). EMT is characterized as a 
reversible process whereby epithelial cells are converted into mesenchymal counterparts 
(83). This process, which is active during embryogenesis and reactivated during 
tumorigenesis, renders non-motile epithelial cells into spindle-like, motile mesenchymal 
cells (84-86). As a result, cells are left with enhanced migratory capabilities, increased 
invasive capacity and resistance to apoptosis (84-86). In the context of prostate cancer 
initiation and progression, longstanding dogma that once suggested that AR signaling 
enhances EMT (87,88) is now being reconsidered (62). Recent clinical studies that 
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measured the expression of E-cadherin and N-cadherin (cell surface markers that reflect 
epithelial and mesenchymal conditions respectively) in tumors from patients treated with 
ADT showed elevated expression of N-cadherin (89). This result, coupled with data from 
a study that showed that knockdown of AR increased EMT markers as well as prostate 
cancer cell migration and invasion (90), provides compelling evidence that inhibiting 
androgen signaling induces EMT. As shown below in Fig. 1.4, the prevailing theory is 
that canonical AR signaling mediates transcriptional programs that work to repress EMT. 
Over time, as ADT represses the androgen/AR axis and resistance mechanisms develop, 
pro-EMT transcriptional programs become activated through aberrant AR signaling, thus 
pushing the cell into a heightened mesenchymal state. For these reasons, it is critical that 
novel, targetable transcriptional mediators that regulate metastatic progression, 
independent of aberrant AR signaling or through alternative pathways that altogether 
bypass the androgen/AR axis, be identified.  
Figure 1.4. AR signaling and EMT. The left cell highlights mechanisms by which 
canonical AR signaling inhibits transcriptional programs mediating epithelial–
mesenchymal transition (EMT). The right cell highlights mechanisms that promote 
EMT, and are induced through aberrant AR signaling, which can come in response to 






CHROMATIN STRUCTURE AND HISTONE MODIFICATIONS 
In eukaryotic cells, nuclear DNA is condensed into chromatin by tightly wrapping 
long double stranded DNA molecules around a core of histone proteins (91,92). The 
assembly of this structure, which is commonly referred to as a nucleosome, provides 
chromatin with a dynamic, modifiable structure and is fundamentally linked to the 
regulation of gene transcription (91-93). The two primary mechanisms for regulating 
chromatin architecture include nucleosomal 
reorganization by ATP-dependent proteins, 
otherwise known as chromatin remodeling 
complexes, and covalent modifications of 
histone proteins by catalytically containing 
enzymes (91-93). Whereas chromatin 
remodeling complexes temporarily alter the 
structure of nucleosomes by physically 
loosening DNA bound to histone cores, histone modifying enzymes, which are 
characterized as “writers” and “erasers”, activate or repress transcription by catalyzing 
the addition or subtraction of various chemical elements to the “tails” of histones as a 
way of altering the affinity between DNA and histones (91-93).  
As illustrated above in Figure 1.5, a nucleosome core is made up of eight histone 
proteins – two molecules each of histones H2A, H2B, H3 and H4 – and is assembled into 
a compact octamer core (91,92). Extending out from each histone core are long positively 
charged N-terminal tails (91,92). Each of these histone tails contains multiple amino acid 
Figure 1.5.  Nucleosome structure. 
Schematic of histone octamer with eight 




residues and are subject to a variety of covalent modifications or post-translational 
modifications (PTMs) (91-94).   
Specifically, PTMs are a form of epigenetic modification that involves the 
reversible bonding of various functional groups, including methyls, ubiquitins and acetyls 
moieties to free 
nitrogen’s in the R-
groups of lysines and 
arginines (Fig 1.6) 
(91-95). Because 
DNA is negatively 
charged and interacts 
so tightly with the 
positive charge of 
histones, nucleosomes 
create a physical barrier 
between regions of DNA and proteins that are tasked with carrying out transcription (91-
94). Therefore, depending on the desired transcriptional outcome, specific histone 
modifying enzymes can be recruited to certain regions of chromatin to disrupt the 
electrical charges on histone residues creating either a more relaxed (euchromatin) or 
compact form of chromatin (heterochromatin) (91-94,96). This form of modulation 
enables eukaryotic cells to exert intricate levels of control over gene expression.  
 
Figure 1.6.  Histone modifications. Schematic of histone 
tails having undergone acetylation, methylation, 




ROLE OF HISTONE ACETYLATION  
The concept of linking RNA synthesis to modifications of histones through 
enzymatic process dates back to the early 1960’s when Vincent Allfrey’s groundbreaking 
work first reported on histone acetylation (97,98). Since then, studies have shown that the 
acetylation of lysine residues is a highly dynamic process and is regulated through 
opposition by histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
(93,98,99). As touched upon in Fig. 1.7 and shown below in more detail in Fig 1.3, upon  
 
receiving biological cues that are favorable for initiating transcription, HATs are brought 
to promotor regions of chromatin to perform the act of acetylation by enzymatically 
transferring acetyl groups from molecules of Acetyl-CoA onto ε-amino groups of lysine 
side chains (98,99). By doing so, the positive charge of lysine is neutralized and the 
overall interaction between DNA and histones is weakened (98,99). This results in the 
loosening of the DNA coil and shifts chromatin into an open or relaxed position (98,99). 
Ultimately, this process allows the necessary transcriptional machinery to directly engage 
Figure 1.7.  Histone acetylation. Schematic of lysine residues along histone 
tails undergoing acetylation. This PTM is processed by a HAT, where upon the 
catalyzation and transfer of an acetyl group from Acetyl-CoA chromatin is 
loosened (Euchromatin). Historically, the addition of acetyl groups is associated 
with relaxed or loosened chromatin, whereas their removal by HDACs further 
condenses or closes chromatin. 
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with the DNA template, thereby putting the cell into a state of active transcription. 
(98,99). 
READERS OF HISTONE ACETYLATION: BROMODOMAINS 
 Whereas HATs convert biological stimuli into PTMs intended to initiate active 
transcription, bromodomain containing proteins recognize and “read” acetylation marks 
for the purposes of  recruiting additional proteins necessary for carrying out transcription 
(98-100). Originally characterized as a maternal effects gene, female sterile (1) homeotic,  
(fsh), in Drosophilia in 1989, and later identified in certain chromatin-modifying factors 
in humans in follow up studies throughout the 1990’s, bromodomains are evolutionary 
conserved structures that bind 
with specificity to acetylation 
marks (100-105). As illustrated in 
Fig 1.8, bromodomains contain a 
conserved sequence of 
approximately 110 amino acids 
and consist of four α-helices (αZ, 
αA, αB and αC) and two variable 
loop regions (ZA and BC) (100-
102,106). Together, these 
structures form a hydrophobic 
pocket that recognizes and 
binds to acetyl-lysine residues 
Figure 1.8.  Bromodomain structure. Tertiary 
structure cartoon of a bromodomain. Bromodomains 
contain a left-handed, four-helix bundle and two 
variable loop regions. These structures form a 




(100,102). In total, there are 61 bromodomains encoded in the human genome that are 
present in 46 different proteins (100,107). While the 46 bromodomain-containing 
proteins cluster into 8 families (groups I-VII), they are more widely characterized by their 
structural domains and are further divided into Bromodomain and Extra-Terminal domain 
(BET) or non-BET families of proteins (93,101).  
BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS STRUCTURE 
 In humans, the BET family of proteins consists of three ubiquitously expressed 
somatic proteins - BRD2 (originally named RING3), BRD3 (ORFX) and BRD4 (MCAP) 
- and one testis specific member, BRDT, that is confined to germ cells (93,100,105,108). 
All four BET family members share common structural features, including two N-
terminal tandem bromodomains (BD1 and BD2) and one extra-C terminal (ET) domain, 
whereas non-BET proteins 
have one or more 
bromodomains and no ET 
domain (Fig. 1.9) 
(93,100,105,106,108,109). 
Functionally, the BD1 and 
BD2 domains specifically 
recognize and bind acetylation groups of lysine residues on histones H3 and H4, while 
the ET domain achieves its regulatory function by recruiting specific effector proteins 
(100,108,110-112). Though the four paralogous proteins share similar amino acid 
sequences and domain organization, the presence of multiple isoforms, including a long 
Figure 1.9.  BET proteins. Schematic showing the 
domain structure of human BET proteins. BET proteins are 




variant of BRD4 that possesses a C-terminal domain (CTD) and sequence variation in the 
interhelical ZA and BC loops that result in distinct structural folds, confers differential 
protein binding sites and non-identical roles regarding transcriptional regulation for each 
family member (92,100,106,108-112). 
BET PROTEINS AND TRANSCRIPTIONAL REGULATION 
 In general, transcription begins or is initiated at a defined position, the 
transcription start site (TSS), at the 5ʹ end of a gene (113,114). The TSS is located within 
a core promoter, which is defined as a short sequence encompassing approximately 50 
basepairs (bp) upstream and downstream from the TSS (113,114). The core promoter is 
where key transcriptional machinery, including general transcription factors (GTFs -
TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH), BET proteins and RNA polymerase II 
(Pol II) associate in order to stabilize and initiate the conversion of DNA sequences into 
RNA transcripts by transcriptional elongation (113,114). The mechanisms by which 
BRD2, BRD3 and BRD4 contribute to this complex process are inherently tied to the 
structural domains of each protein and the broader cellular fate – DNA replication, cell 
cycle progression, proliferation, cell differentiation, etc. – that has been elicited from 
external biological cues. In the context of BRD2 and BRD3, many of the first studies that 
explored their functionality discovered that these proteins were enriched in several 
acetylation marks (H4K5, H4K12 and H3K14) associated with gene transcription and 
that they played a major role in regulating cell cycle progression and cellular 
differentiation (105,115-118). Specifically, it was shown that the ET domain of BRD2 
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interacts with E2F, a 
transcription factor that 
facilitates the G1/S transition, 
to activate cell cycle regulatory 
genes that contain E2F binding 
sites in their promoters (Fig. 
1.10) (115,116,119). In another 
study, the BD1 domain of 
BRD3 was shown to directly 
interact with the transcription 
factor GATA1 (120). This 
complex, which engages 
chromatin through GATA1, was shown to regulate the expression of all erythroid and 
megakaryocyte-specific genes (120,121). These findings were significant in that they 
revealed that BRD2 and BRD3 serve as nucleosome chaperones and help facilitate Pol II 
to elongate transcripts (115-117,119). Like BRD2 and BRD3, BRD4 was also discovered 
early on to serve as a nucleosome chaperone protein important for mitotic exit, as its 
expression was shown to affect the G2/M transition (111,122,123). However, because 
BRD4 also contains a CTD and had previously been reported to be a part of the Mediator 
complex (MED) (multiprotein complex that interacts with Pol II and general transcription 
factors), it was thought that BRD4 may have a more direct role in regulating transcription 
initiation and elongation (100,124).  
Figure 1.10.  Model of BRD2 transcription 
complex. Schematic diagram showing a summary of 
proteins associated with BRD2 for the transcriptional 
regulation of the cell cycle gene  cyclin A. 
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As mentioned above, Pol II in concert with the six GTFs, assemble at the TSS 
along a gene's core promoter to initiate transcription (113,114). Shortly after this process, 
serine residues on the CTD of Pol II are phosphorylated by TFIIH, which enables Pol II 
to dissociate from the GTFs and continue transcribing (113,114). Once Pol II synthesizes 
a short stretch of RNA (approximately 30 – 50 nucleotides), it then enters a phase that is 
referred to as promoter-proximal pause and pause-release (113,114). This phase is critical 
as it marks the transition from initiation to elongation/promoter clearance and is where 
BRD4 was discovered to play a major role in regulating transcription (125,126). 
Discovered by Jang and colleagues in 2005 and illustrated below in Fig. 1.11, once 
paused, Pol II forms an inactivating complex with positive transcription elongation factor 
b (P-TEFb), 7SK and HEXIM (46,113,114). To exit this paused state, BRD4 in complex 
with JMJD6 (112,127), recruits and interacts through its CTD with the core subunits of P-
TEFb, CDK9 and Cyclin T1 (125,126,128). The formation of this complex enables 
CDK9 to phosphorylate Ser2 along the CTD of Pol II (125-127,129). This reaction frees 
up Pol II and allows it to enter into a state of productive elongation (125-127,129).  
 
Figure 1.11. BRD4 transcriptional regulation. Schematic of BRD4 in complex with 
P-TEFB and other cofactors at the promoter-proximal region. The presence of BRD4 enables 
P-TEFb to become activated through a series of phosphorylating events by CDK9 along 
serine residues on the CTD of Pol II. This action allows Pol II to exit a paused state and 
continue transcribing through transcriptional elongation. 
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BET PROTEINS, CANCER AND THERAPEUTIC TARGETS  
 Building off of decade’s worth of discoveries that showed that BET proteins, and 
in particular BRD4, regulate transcription by serving as nucleosome chaperones for Pol II 
guided elongation through both P-TEFb dependent and independent mechanisms 
(112,125,126,130,131), researchers quickly recognized that BET proteins may also 
contribute to many oncological malignancies. Evidence to support this rationale 
developed rapidly, when in addition to discovering that BRD4 directly engages with P-
TEFb and facilitates transcriptional elongation, it was also shown that loss of BRD4 
prevents P-TEFb from engaging with the C-MYC locus during G1 (125,126). c-Myc is a 
multipurpose transcription factor that promotes cell proliferation and cell cycle 
progression, and is frequently implicated in human oncogenesis when aberrantly 
expressed (132). Moreover, around the same time when BRD4 was identified as being a 
key player for Pol II pause-release and regulator of c-Myc expression (125,126), 
researchers also discovered that BRD3 and BRD4 contribute to nuclear protein in testis 
(NUT) midline carcinoma (133,134). This form of malignancy comes as a byproduct of 
reciprocal translocations between NUT and BRD3/BRD4, and leads to a highly aggressive 
form of cancer led by C-MYC activation through the BRD3/BRD4-NUT fusion protein 
(133-135).  
 With attention already on Myc as an anti-cancer target (136), and with the 
findings that revealed that the BET proteins contain oncogenic properties through their 
regulation of growth-promoting genes/c-Myc (117,125,126,133,134), the motivation for 





were developed (137,138). JQ1 and 
I-BET are pan-BET inhibitors that 
competitively bind with high 
affinity and selectivity to the BD1 
and BD2 domains present in BET 
proteins as compared to other non-
BET proteins (137,138). By 
preventing BET proteins from 
tethering to acetylated lysines 
along histone tails (Fig. 1.12), data 
quickly emerged to show that 
inhibitors like JQ1 had strong anti-
cancer effects on multiple myeloma (MM) (139), acute myeloid leukemia (AML) 
(140,141), Burkitt’s lymphoma (140), mixed lineage leukemia (MLL) (142), 
medulloblastoma (143), triple negative breast cancer (144) and CRPC (145-147). Though 
these findings generated much excitement among both research and medical 
communities, the prevailing theme across the majority of these studies focused on the 
downregulation of c-Myc and the anti-proliferative effects of JQ1 (139,140). This 
emphasis is noteworthy because, even though c-Myc plays a significant role in cancer 
progression (132), it is unlikely that the anti-proliferative effects observed by JQ1 are 
Figure 1.12.  BET inhibition.  JQ1 competitively 
binds to the acetyl-lysine recognition pockets present 
in BET proteins. This interaction blocks BET proteins 
from interacting with chromatin and represses the 
expression of oncogenes like c-Myc. 
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resolved solely by c-Myc inhibition. Making matters more complicated is the fact that 
pan-BET inhibitors obfuscate individual BET protein function (148,149), and as 
described in the last two subchapters, their use in a variety of prostate cancer models has 
led to the misleading notion that BRD2, BRD3 and BRD4 always overlap in function 
(145).  
BET PROTEINS AND PROSTATE CANCER 
Shortly after the development of JQ1 in 2010, four separate groups published 
reports showcasing how pan-BET inhibition provided anti-cancer effects in a variety of 
prostate cancer cell lines and xenograft models (145-147,150). The findings from these 
reports included the common theme of c-Myc reduction, and likewise, reduced prostate 
cancer cell proliferation and growth, however, they also linked together for the first time 
BET proteins and AR-mediated transcription (145-147,150). Through chromatin 
immunoprecipitation-sequencing (ChIP-seq) and gene set enrichment analysis (GSEA) 
experiments, it was shown that BRD4, and to a lesser extent BRD2 and BRD3, serve as 
co-activators of AR-mediated transcription by physically interacting with the N-terminal 
domain of AR (145). Numerous follow up studies continued to highlight the use of pan-
BET therapies in pre-clinical models of prostate cancer, with findings that included 
reduced AR-V chromatin binding (151,152) and abrogation of TMPRSS2-ERG fusion 
proteins (153). As a result, a new class of pan-BET therapies based on proteolysis-
targeting chimera (PROTAC) technology was developed (154). These therapies, which 
link together ligands for targeted proteins with ligands for an E3 ubiquitin ligase 
complex, have been shown to induce proteasomal degradation of BET proteins in a 
 
 24 
variety of prostate cancer models (155). Furthermore, the establishment of BET 
PROTACs for the purposes of treating prostate cancer was especially important, given 
that previous studies determined that Cullin 3SPOP or SPOP (protein that marks BRD2, 
BRD3 and BRD4 for proteasomal degradation) is commonly mutated in clinical cases of 
prostate cancer and confers resistance to pan-BET inhibitors (156,157). While these 
studies identified significant roles for BET proteins in prostate cancer development and 
progression, and likewise have made a strong case for incorporating BET therapies into 
the standard of care for treating men with advanced prostate cancer, they failed to provide 
a complete picture regarding the individual roles of BET proteins in regulating prostate 
cancer dissemination. 
SCOPE OF THIS DISSERTATION 
 Through years of investigative studies, it is now understood that AR adaptations 
that arise in response to ADT are not singular, but diverse, and include: gene 
amplification, mutation and complete loss of receptor expression. Collectively, each of 
these AR adaptations contributes to a complex, heterogenous, ADT-resistant tumor that 
culminates in the development of mCRPC. Furthermore, it is also been shown that BRD4 
expression associates with prostate cancer patient outcomes and increase with castration 
resistance (156,158).  Yet, the overwhelming majority of studies mentioned above that 
established roles for BET proteins in the context of prostate cancer development and 
progression, did so by predominantly using models of prostate cancer that express full-
length AR or wild-type AR and rarely explored how each of BRD2, BRD3 and BRD4 
contributes to a specific biological function (145). As we have noted on multiple 
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occasions, JQ1 is not BRD4 selective (137,159). Furthermore, BET proteins modulate 
distinct signaling pathways and can even have non-overlapping and opposing functions 
(148,149).  
Therefore, to better understand the roles that BET proteins have in regulating 
prostate cancer dissemination, we examined how each of BRD2, BRD3 and BRD4 
contributes to prostate cancer dissemination by using prostate cancer cell lines that model 
common CRPC subtypes, each with different AR composition. By employing a BET-
specific siRNA knockdown approach to target each BET protein individually, we 
determined that only BRD4 regulates cell migration and invasion across all models of 
CRPC, regardless of aggressiveness and AR status, whereas BRD2 and BRD3 only 
regulate migration and invasion in less aggressive models that retain AR expression or 
signaling. Remarkably, we also discovered that in some cases, depletion of BRD2 
opposes the migratory effects of BRD4, and actually increases prostate cancer cell 
migration. To identify potential BRD4-targets important for prostate cancer cell 
migration and invasion, we carried out a gene expression analysis in BET protein-
depleted cells. By curating a panel of 73 genes that we previously showed were involved 
in pathways important for cell migration, invasion and metastasis, we identified AHNAK, 
a 700 kDa scaffolding protein (160), as a BRD4-specific target gene. We then confirmed 
that this relationship is conserved even in the absence of AR expression, proved that 
AHNAK is critical for CRPC cell migration and invasion and discovered that high 
expression of BRD4 and AHNAK associates with survival outcomes in patients with 
advanced prostate cancer. 
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Lastly, we investigated how each of BRD2, BRD3 and BRD4 govern the 
transcriptional programs that control EMT. As noted above, prolonged ADT facilitates 
the activation of pro-EMT transcriptional programs, which includes members of the SNAI 
family (84), causing cells to become more migratory and invasive. By once again using 
prostate cancer cell lines with different AR composition, we found that only BRD4 – and 
not BRD2 or BRD3 - regulates the expression of Snail and Slug. Moreover, we also 
showed that the downregulation of these transcription factors significantly increases the 
expression of the pro-epithelial marker, E-cadherin. Finally, we discovered that the 
expression of this BRD4 regulated EMT “gene signature” significantly correlates with 
recurrence and progression in patients with aggressive prostate cancer. Overall, these 
studies have shed new insights in the molecular mechanisms of BET proteins, and in 
particular BRD4, in the context of prostate cancer dissemination and have provided 
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The inevitable progression of advanced prostate cancer to castration resistance, 
and ultimately to lethal metastatic disease, depends on primary or acquired resistance to 
conventional androgen-deprivation therapy (ADT) and accumulated resistance strategies 
to evade androgen receptor (AR) suppression. In prostate cancer cells, AR adaptations 
that arise in response to ADT are not singular, but diverse, and include gene 
amplification, mutation and even complete loss of receptor expression. Collectively, each 
of these AR adaptations contributes to a complex, heterogenous, ADT-resistant tumor. 
Here, we examined prostate cancer cell lines that model common castration-resistant 
prostate cancer (CRPC) subtypes, each with different AR composition, and focused on 
novel regulators of tumor progression, the Bromodomain and ExtraTerminal (BET) 
family of proteins. We found that BRD4 regulates cell migration across all models of 
CRPC, regardless of aggressiveness and AR status, whereas BRD2 and BRD3 only 
regulate migration and invasion in less aggressive models that retain AR expression or 
signaling. BRD4, a co-regulator of gene transcription, controls migration and invasion 
through transcription of AHNAK, a large scaffolding protein linked to promotion of 
metastasis in a diverse set of cancers. Furthermore, treatment of CRPC cell lines with low 
doses of MZ1, a small-molecule, BRD4-selective degrader, inhibits metastatic potential. 
Overall, these results reveal a novel BRD4-AHNAK pathway that may be targetable to 





Prostate cancer is the second leading cause of cancer-related mortality in men in 
the United States (1). For patients who have recurrent prostate cancer or a disseminated 
form of the disease, the standard of care is androgen-deprivation therapy (ADT) (2). 
Despite an initial, nearly universal response that patients show to the anti-androgen drugs 
abiraterone, which inhibits the production of androgens, and enzalutamide, which 
prevents the androgen receptor (AR) from nuclear translocation and activation of AR-
dependent genes (3), most patients invariably progress to castration-resistant prostate 
cancer (CRPC) and to a metastatic and incurable form of the disease (4,5). Prostate tumor 
cells acquire resistance to ADT through multiple mechanisms. These mechanisms, which 
are critical to cancer progression, include but are not limited to: aberrant androgen 
synthesis, AR gene amplifications, AR mutations, production of constitutively active AR 
splice variants and alternative steroid receptors (6-8). Whereas the majority of acquired 
mechanisms reactivate AR signaling and upregulate AR-dependent pro-metastatic and 
survival genes (9), recent data suggests that loss of AR expression due to sustained 
repression of AR signaling is an emerging mechanism of ADT resistance (10). Consistent 
with this finding, previous studies have demonstrated that some metastatic CRPC 
(mCRPC) tumors fail to express AR after ADT, or possibly even beforehand (11,12). 
Therefore, identification of novel, targetable mechanisms that critically regulate 
metastatic progression may offer valuable options to treat mCRPC, independent of 




Bromodomain and Extraterminal domain (BET) proteins (BRD2, BRD3, BRD4 
and testis-specific BRDT) are a family of chromatin-associated proteins that regulate 
gene expression by acting as epigenetic readers through their ability to detect and bind to 
acetylated lysine residues on nucleosomal histone tails (13,14). Much effort has been 
invested in potential anti-cancer therapies that target BET proteins because of their roles 
as co-regulators of cell cycle progression (15) and cell proliferation (16). Consistent with 
this approach, small molecule pan-BET inhibitors such as JQ1 (17) and I-BET151 (18) 
have shown great promise as therapeutic agents across a diverse array of human 
malignancies (19,20), including CRPC (21,22). In cell line models of CRPC, JQ1 has 
been found to repress AR-V7 (an AR splice variant resistant to ADT (23)) expression 
(24) and AR-mediated gene transcription (25). More recently, ARV-771, a pan-BET 
degrader built on proteolysis-targeting chimera (PROTAC) technology, inhibited tumor 
growth in mouse models of CRPC (22). However, even as pan-BET inhibitors and 
degraders become more widespread in their investigational and clinical use (26), 
accumulating evidence shows that pan-BET therapies can produce off-target effects, 
including the reactivation of latent HIV in infected T cells (27), and obscure the biology 
of each independently-acting BET protein (28). This caution underscores the need for 
more BET family member-selective chemical intervention (29).  
Here, we investigate BET proteins as regulators of prostate cancer cell 
dissemination across multiple cell line models of CRPC. Notably, we show that BRD4, 
but not BRD2 or BRD3, regulates CRPC cell migration in all models. We identified 
AHNAK, a 700 kDa scaffolding protein that has been linked to migration and invasion in 
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other aggressive cancers, as a BRD4-target gene to regulate CRPC cell migration and 
invasion. Survival analysis of prostate cancer cases with Cox proportional hazard models 
supports this interpretation. Furthermore, we provide evidence that the selective 
degradation of BRD4 with the innovative small molecule MZ1 (30) efficiently blocks 
CRPC metastatic potential. Overall, these results reveal a novel mechanism that could be 



















MATERIALS AND METHODS 
Cell Culture 
 Human prostate cancer cell lines maintained at the NCI Office of Physical 
Sciences-Oncology centers (PS-OC) Network Bioresource Core Facility (PBCF) were 
contractually obtained through the American Type Culture Collection, under a Material 
Transfer Agreement. The cell lines have been authenticated by the NIH Physical Sciences 
Oncology Consortium. The 22Rv1, DU 145 and PC-3 prostate cancer cell lines were 
cultured in RPMI-1640 medium (Gibco). VCaP prostate cancer cells were cultured in 
DMEM medium (Gibco). All culture media were supplemented with 10% fetal bovine 
serum (FBS, Corning) and 1% antibiotics (penicillin/streptomycin, Gibco). Cell lines 
were grown at 37°C in 5% CO2. Mycoplasma contamination was prevented by treating 
cells with plasmocin (5 µg/mL for 2 weeks, Invivogen) after thawing and prior to 
experiments.  
Antibodies and Reagents 
The following antibodies were used: anti-BRD2, BRD3 and BRD4 (Bethyl 
Laboratories), anti-AR, anti-Flag and anti-β-Actin (Cell Signaling), anti-AHNAK 
(Abcam) and anti-α-tubulin (Santa Cruz Biotechnology). HRP-conjugated secondary 
antibodies were purchased from Bio-Rad. Fluorochrome-conjugated secondary antibodies 
were obtained from Jackson Laboratories. The active form of JQ1 ((+)-JQ1), the inactive 
form ((–)-JQ1) and MZ1 were purchased from Tocris. 
Plasmids, siRNAs and Transfection 
Lentivirus-mediated Flag-AHNAK expressing plasmid (EX-V0190-Lv242) and 
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control vector (EX-NEG-Lv242) were purchased from GeneCopoeia. HEK-293 cells 
were co-transfected with plasmids encoding for VSV-G, dR8.2 dvpr and either Flag-
AHNAK or control plasmid using Lipofectamine 2000 reagent (Thermo Fischer 
Scientific). Viral supernatants were collected, and together with 4 µg/mL Polybrene 
(Millipore), were used to infect DU 145 cells for 48 hours. Stable clones were selected 
using medium containing 1 µg/mL puromycin (Invivogen). ON-Targetplus Human BET, 
Non-Targeting (scramble) and Human AHNAK SMARTpool siRNAs were purchased 
from Dharmacon. Cells were transfected with 25 nmol/L of listed siRNA for 72 hours 
with Lipofectamine 2000. 
Immunoblotting 
Cell pellets were lysed in RIPA buffer (50 mmol/L Tris/HCl pH 7.5, 1 mmol/L 
EDTA, 0.5 mmol/L EGTA, 150 mmol/L NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 
1% Triton X-100). Samples containing 25 µg of protein were resolved by SDS-PAGE 
and transferred to nitrocellulose membranes. Membranes were saturated in TBS-BSA 5% 
to block non-specific binding sites, probed with primary antibodies and then visualized 
with HRP-conjugated secondary antibodies. Upon incubation in ECL, membranes were 
quantified with a gel imager. 
qRT-PCR 
Total RNA was extracted using the RNAeasy Kit (Qiagen). Reverse transcription 
reactions were performed with 1 µg of total RNA with the QuantiTect Reverse 
Transcription kit (Qiagen). The following genes were detected using the corresponding 




3’), BRD3 (forward: 5’-CCTCAGGGAGATGCTATCCA-3’, reverse: 5’-
ATGTCGTGGTAGTCGTGCAG-3’), BRD4 (forward: 5’-
TTTGAGACCCTGAAGCCGTC-3’, reverse: 5’-TTAGGCAGGACCTGTTTCGG-3’), 
AHNAK (forward: 5’-GTGACCGAGATTCCCGACGA-3’, reverse: 5’-
AGCTCCCGGGTTGTCTCCTC-3’); the mean expression of the following housekeeping 
genes were used to normalize the results: ACTB (forward: 5’-
ATTGGCAATGAGCGGTTCC-3’, reverse: 5’-GGTAGTTTCGTGGATGCCACA-3’), 
YWHAZ (forward: 5’-ACTTTTGGTACATTGTGGCTTCAA-3’, reverse: 5’-
CCGCCAGGACAAACCAGTAT-3’). PCR amplifications were performed with MESA 
Green qPCR MasterMix (Eurogentec) on an ABI Prism 7500 thermal cycler. 
Migration/invasion gene screening assay was performed using the RT2 Profiler 
PCR EMT Array (Qiagen). 
Chromatin Immunoprecipitation 
DU 145 cells were treated with 400 nM of either (-)JQ1 or (+)JQ1 for 24 hours, 
fixed in 0.75% formaldehyde for 10 minutes, quenched with 125 mM glycine for 5 
minutes and then lysed for chromatin immunoprecipitation (ChIP) as previously reported 
(31). Chromatin was precipitated with 1 µg anti-rabbit IgG (Cell Signaling) or anti-BRD4 
(Bethyl Laboratories) with Protein A/G magnetic beads (Thermo Fisher Scientific). 5 ng 
of each sample was analyzed in triplicate by qPCR. The fold difference was calculated as 
2^[Ct(input) - Ct(ChIP)], and fold enrichment over anti-IgG was assessed. ChIP primer 





Cells were fixed in absolute methanol for 5 minutes at - 20°C and then 
permeabilized with PBS, 0.2% Triton X-100 buffer for 10 minutes. After saturation in 
blocking buffer (0.02% Triton X-100, 2% BSA in PBS) for 30 minutes, permeabilized 
cells were incubated with primary antibodies and then fluorochrome-conjugated 
secondary antibodies (diluted in blocking buffer) for 1 hour. Lastly, coverslips were 
mounted with ProLong Gold with DAPI (Thermo Fischer Scientific). Image acquisition 
was conducted using a Leica DM IL LED inverted microscope. Fluorescence intensities 
were determined using ImageJ software (NIH). Intensities were measured from 
individual cells, corrected for background signal, and normalized by cell area.  
Migration and Invasion Assays 
JQ1: 22Rv1 and DU 145 cells were maintained in serum-free media + 400 nM of 
either active or inactive JQ1 for 3 hours prior to the beginning of experiments to suppress 
any basal migratory signals. VCaP cells were maintained in complete medium + 400 nM 
of either active or inactive JQ1 for 3 hours prior to the beginning of experiments. VCaP 
and 22Rv1 (225,000) or DU 145 (75,000) cells were seeded in Transwell inserts (pore 
size 8 µM, Corning) and challenged for migration. VCaP cells were exposed to FBS for 
48 hours, 22Rv1 cells were exposed to 10% FBS for 24 hours, and DU 145 cells were 
exposed to 2.5% FBS for 6 hours.  
siRNA: VCaP, 22Rv1 and DU 145 cells were seeded into Transwell inserts 72 
hours after transfection using the conditions listed above. PC-3 cells (75,000) were 
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maintained in serum-free media for 3 hours and then exposed to 10% FBS for 24 hours. 
For invasion assay, Matrigel (Corning) was diluted in serum-free media to a final 
concentration of 0.5 mg/mL and 100 µL was added onto the upper membranes prior to 
cell plating. Invasion was conducted for 16 hours using DU 145 cells using the 
corresponding conditions described above. 
MZ1: 22Rv1 and DU 145 cells were treated with either 0.01% DMSO (control) or 
10 nM (22Rv1) or 100 nM (DU 145) of MZ1 for 21 hours. Cells were then maintained in 
serum-free media with the aforementioned MZ1 concentration for 3 hours and then 
seeded into Transwell inserts using conditions listed above. VCaP cells were treated with 
either 0.01% DMSO or 10 nM MZ1 for 24 hours in complete medium and then seeded 
into Transwell inserts using corresponding conditions listed above. Invasion was 
conducted using the corresponding conditions described above.  
Cells that did not migrate or invade were removed by wiping the upper side of the 
membrane with a cotton swab. Remaining cells were then fixed in absolute methanol for 
5 minutes at -20°C. Cells were then stained with 1% crystal violet (Sigma) in 2% ethanol 
for 10 minutes. Images were captured using an EVOS XL Core digital inverted 
microscope. The percentage of migration and invasion was determined by first 
calculating the sum of the area of total migrated/invaded cells on the entire membrane by 
using ImageJ software, and then converted to relative percent migration/invasion by 





MTT Cell Viability Assays 
siRNA: VCaP, 22Rv1, DU 145 and PC-3 cells (15,000) were seeded in 96 well 
plates 24 hours (VCaP) or 48 hours (22Rv1, DU 145 and PC-3) after transfection. 
MZ1: VCaP, 22Rv1 and DU 145 cells (15,000) cells were seeded in 96 well 
plates and then exposed to MZ1 at optimal BRD4-selective concentrations for 24 hours.  
Post transfection (72 hours) or MZ1 treatment (24 hours), cells were then 
incubated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 
3 hours. Light absorbance was then measured at 570 nm and corrected for background 
absorbance at 690 nm with a multiwell spectrophotometer. 
Kaplan-Meier and Clinical Parameter Analysis 
To investigate the correlation between biochemical recurrence-free survival and 
BRD4 and AHNAK expression, we utilized data from 421 patients from the TCGA 
repository. The normalized expression values of the RNAseq ID 23476 (for BRD4) and 
79026 (for AHNAK) were used. For each gene, cutoff values were determined separately 
as described previously (32). Then, in order to assess the potential additive effects of the 
genes, samples with high BRD4 and high AHNAK were combined into one cohort, 
samples with low BRD4 and low AHNAK were combined into a second cohort, and all 
remaining patients with either high or low BRD4 and either high or low AHNAK were 
combined into a third cohort. Cox regression was used to compare the length of survival 
of the cohorts and a Kaplan-Meier plot was drawn to visualize the difference. As it is 
only possible to compute a hazard ratio (HR) for two groups, HR and p value are shown 
for biochemical recurrence-free survival by comparing the BRD4high and AHNAKhigh and 
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the BRD4low and AHNAKlow cohorts. To exclude BRD4 or AHNAK mutation bias, we 
determined that less than 1% of the 421 patients profiled had mutations in either BRD4 or 
AHNAK (data not shown). 
We compared the expression of both genes to Gleason score, pathological T and 
N status. Sample number with a positive event for pathological M was too low for 
meaningful analysis. Expression values were compared by a Kruskal-Wallis H-test 
(Gleason and T pathological) and Mann-Whitney T-test (N pathological). Finally, we 
used the patient samples to directly compare BRD4 and AHNAK expressions by drawing 
a linear regression and computing a Spearman rank correlation. The gene expression data 
with clinical annotation including pathological TNM, Gleason score and survival times 
are listed in Supplementary Tables S1 and S2. 
Statistical Analysis 
Statistical analyses of the in vitro experiments were performed using Student’s t 
test or ANOVA as indicated, and were generated by GraphPad Prism software. p < 0.05 






Pan-BET inhibition reduces prostate cancer cell migration in multiple models of 
CRPC 
CRPC is an advanced and aggressive form of prostate cancer associated with poor 
survival outcomes (33). Genomic analyses of mCRPC tumors from patients who have 
undergone ADT reveal that AR is heterogeneous in both status (over 60% of profiled 
tumors have either a mutation or amplification of AR (34,35)) and expression (over 20% 
of profiled tumors fail to express AR (10)). To determine whether BET proteins regulate 
CRPC cell migration, we used different cell line models that capture some of the AR 
heterogeneity of CRPC (VCaP: AR-Wild-type/Amplified (WT/Amp); 22Rv1: AR-mutant 
(H874Y) and DU 145: AR-null (36,37) (Fig. 2.1A). Our approach was first to use the pan-
BET inhibitor JQ1, a small molecule that displaces BRD2, BRD3 and BRD4 from 
chromatin (17), to evaluate its effect on prostate cancer cell migration. VCaP, 22Rv1 and 
DU 145 cells were pretreated with either the active (+) form or inactive (-) form of JQ1 for 
3 hours, and then challenged for migration using a transwell system. (+)JQ1 reduced 





2.1B-D). Taken together, these data indicate that BET protein functions are essential for 
CRPC cell migration. 
BRD4 regulates CRPC cell migration irrespective of AR status 
Upon 
confirming that 
BET proteins are 
critical for CRPC 
cell migration, we 
determined 
whether each BET 
protein is needed 
for migration in 
each model. JQ1 is 
not a BET isoform-
selective inhibitor  
Figure 2.1. Pan-BET inhibition reduces prostate cancer cell migration in multiple 
models of CRPC. A, Endogenous expression of BET proteins and AR in multiple prostate 
cancer cell lines was detected by immunoblotting. Molecular weights (MW) in kDa 
corresponding to the immunoblotted proteins are indicated. (B-D) VCaP, 22Rv1 and DU 145 
cells were pre-treated with either 400 nM of (-)JQ1 or (+)JQ1 in complete medium (VCaP) or 
serum-free conditions (22Rv1 and DU 145) for 3 hours. VCaP, 22Rv1 and DU 145 cells were 
then challenged for migration for 48 hours, 24 hours and 6 hours in pure FBS, 10% FBS or 
2.5% FBS, respectively, using a transwell system. Results are shown as a relative percentage 
of migration in comparison to (-)JQ1. Left panel: representative images of the total membrane 
area showing migrated cells stained with crystal violet. Right Panel: Bars represents means ± 
SEM of three independent experiments. Statistical analyses were performed using the 
Student’s t test. Significant differences: *, P < 0.05; ***, P < 0.001. 
 
Figure 2.2. Validation of BET protein depletion by BET-
specific siRNAs. (A-D) Relative mRNA expression of BRD2, 
BRD3 and BRD4 in control scramble or BET depleted VCaP, 22Rv1, 
DU 145 and PC-3 cells. Bar represents means ± SEM of three 
independent experiments. Statistical analyses were performed using a 
one-way ANOVA. Statistical analyses were performed using the 




(17), thus, we used a BET-specific siRNA knockdown approach to target each BET 
protein individually. Transfection of VCaP, 22Rv1 and DU 145 cells with control 
scramble siRNA or BET-specific siRNAs selectively ablated the mRNA (Fig. 2.2A-D) 
and protein of each BET gene (Fig. 2.3A-C). Cell viability was assessed by MTT assay 
under the aforementioned transfection conditions to ensure that any ensuing migratory 
effect was a result of BET protein depletion and not due to cell death. Viability of control 
and BET depleted VCaP, 22Rv1 and DU 145 cells was comparable across all conditions 
Figure 2.3. BRD4 regulates CRPC cell migration irrespective of AR status. (A-
C) BET protein-depletion by siRNA validated by immunoblotting in VCaP, 22Rv1 and DU 
145 cells. Cells were transfected with either 25 nM of control (scramble) siRNA or the 
indicated BET-specific siRNAs for 72 hours. Quantifications relative to scramble with 
normalization using β-actin levels as a loading control are indicated. Blots shown are 
representative of three independent experiments. (D-F) MTT assay showing the of viability 
in VCaP, 22Rv1 and DU 145 cells transfected with either BET-specific siRNAs or scramble 
using the conditions described above. Results are shown as relative percentage of viability 
in comparison to scramble.  Bar represent means ± SEM of three independent experiments. 
Statistical analyses were performed using a one-way ANOVA. (G-I) VCaP, 22Rv1 and DU 
145 cells were transfected with either scramble or BET-specific siRNAs for 72 hours and 
then challenged for migration. Results are shown as a relative percentage of migration in 
comparison to scramble. Representative images are shown as a percentage of migrated area 
in comparison to the total membrane area. Bar represents means ± SEM of three independent 
experiments. Statistical analyses were performed using a one-way ANOVA. Significant 




(Fig. 2.3D-F). We next measured the migratory capacity of BET protein-depleted cells in 
each model with the Transwell system. Individual depletion of either BRD2, BRD3 or 
BRD4 significantly reduced migration in VCaP cells (Fig. 2.3G), matching an invasive 
phenotype previously reported (25). Depletion of either BRD2 or BRD4 in 22Rv1 cells 
reduced migration by 53%, whereas knockdown of BRD3 had no effect on migration 
(Fig. 2.3H). Interestingly, whereas migration in VCaP and 22Rv1 cells was regulated by 
more than one BET protein, the knockdown of only BRD4 - and not of BRD2 or BRD3 - 
significantly reduced DU 145 cell migration (Fig. 2.3I). The same phenotype was also 
observed when measuring invasion (Fig. 2.4A). Furthermore, a similar BRD4-dependent 
migration phenotype was also observed in PC-3 cells (highly metastatic, AR-null) (Fig. 
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2.4B-D). Remarkably though, depletion of BRD2 opposed the effect of BRD4 in this 
model, and increased migration by 48% (Fig. 2.4B-D). Collectively, these results identify 
BRD4, and not BRD2 or BRD3, as the dominant regulator of CRPC cell migration and 
invasion, and also illustrates the complex, non-overlapping and even opposing functions 
that BET proteins can have in their regulation of a particular biological process.  
Discovery of AHNAK as a BRD4 target gene 
In order to identify BRD4 target genes that mediate CRPC cell dissemination, we 
carried out a gene expression analysis in control and BET protein-depleted DU 145 cells. 
We curated a panel of 73 genes that we previously showed were involved in pathways 
important for cell migration, invasion and metastasis (31). Depletion of BRD4 by siRNA 
Figure 2.4. BRD4 regulates DU 145 cell invasion and PC-3 cell migration. A, DU 
145 cells were transfected with either control scramble or BET-specific siRNAs for 72 hours 
and then challenged for invasion for 16 hours. Results are shown as a relative percentage of 
invasion in comparison to control. Representative images are shown as a percentage of invaded 
area in comparison to the total membrane area. Bar represents means ± SEM of three 
independent experiments. Statistical analyses were performed using a one-way ANOVA. B, 
BET protein-depletion by siRNA in PC-3 cells validated by immunoblotting. Cells were 
transfected with either 25 nM of control (scramble) siRNA or the indicated BET-specific 
siRNAs for 72 hours. Quantifications relative to scramble with normalization using β-actin 
levels as a loading control are indicated. Blots shown are representative of three independent 
experiments. C, MTT assay showing the viability of PC-3 cells transfected with BET-specific 
siRNAs using the conditions described previously. Results are shown as relative percentage of 
viability in comparison to scramble. Bar represent means ± SEM of three independent 
experiments. Statistical analyses were performed using a one-way ANOVA. D, PC-3 cells were 
transfected with either control scramble or BET-specific siRNAs for 72 hours and then 
challenged for migration. Results are shown as a relative percentage of migration in comparison 
to scramble. Representative images are shown as a percentage of migrated area in comparison 
to the total membrane area. Bar represents means ± SEM of three independent experiments. 
Statistical analyses were performed using a one-way ANOVA. Significant differences: ns, 





Figure 2.5. Discovery of AHNAK as a BRD4 target gene. A, Heatmap representing the 
relative expression of 73 genes involved in the regulation of migration in response to BET 
protein-depletion in DU 145 cells. Z scores are represented using a color code. Results from 
two independent experiments are shown. (B-D) AHNAK relative mRNA expression measured 
in VCaP, 22Rv1 and DU 145 cells 72 hours after transfection with the indicated siRNAs 
(scramble; siBRD2, 25 nmol/L; siBRD3, 25 nmol/L; siBRD4, 25 nmol/L). Bar represent means 
± SEM of three independent experiments. Statistical analyses were performed using a one-way 
ANOVA. (E-G) Immunofluorescence images showing the expression of AHNAK in VCaP, 
22Rv1 and DU 145 cells 72 hours after transfection with the indicated siRNAs (scramble; 
siBRD2, 25 nmol/L; siBRD3, 25 nmol/L; siBRD4, 25 nmol/L). AHNAK is stained in red and 
nuclei is stained in blue with DAPI in the merged images (lower panels). Scale bar, 100 µm. 
Quantification of AHNAK immunofluorescence reflected as a percentage of relative 
fluorescence intensity (%RFI). Bar represents means ± SEM of individual cells (n ≥ 600 -
VCaP; n ≥ 400 – 22Rv1 and n ≥ 800 – DU 145). Results from two independent experiments 
are shown. Statistical analyses were performed using a one-way ANOVA. Significant 





knockdown produced a significant change in the expression of three genes when 
compared to BRD2 and BRD3 depleted cells (two upregulated, one downregulated, Z 
score ≥ 2 or ≤ -2, Fig. 2.5A). Of the three differentially expressed genes, only AHNAK, a 
700 kDa scaffolding protein was downregulated (38). Known primarily for its ability to 
facilitate the formation of multi-protein complexes (39,40), AHNAK more recently has 
been shown to be important for the development of pseudopodial protrusions and tumor 
cell migration and invasion (41,42). Therefore, we considered that this potential target 
gene had important translational significance worth deeper investigation. To verify our 
findings that AHNAK is a BRD4 target gene, we first measured AHNAK mRNA and 
protein expression in each of our models upon BET protein depletion. Indeed,  
Figure 2.6. BRD4 regulates AHNAK in PC-3 cells and interacts with the AHNAK 
promoter in DU 145 cells. A, AHNAK relative mRNA expression measured in PC-3 cells 
72 hours after transfection with the indicated siRNAs (scramble; siBRD2, 25 nmol/L; siBRD3, 
25 nmol/L; siBRD4, 25 nmol/L). Statistical analyses were performed using a one-way 
ANOVA. B, Immunofluorescence images showing the expression of AHNAK in PC-3 cells 
72 hours after transfection with the indicated siRNAs (scramble; siBRD2, 25 nmol/L; siBRD3, 
25 nmol/L; siBRD4, 25 nmol/L). AHNAK is stained in red and nuclei is stained in blue with 
DAPI in the merged images (lower panels). Scale bar, 100 µm. Quantification of AHNAK 
immunofluorescence reflected as a percentage of relative fluorescence intensity (%RFI). Bar 
represents means ± SEM of individual cells (n ≥ 700). Results from two independent 
experiments are shown. C, DU 145 cells were treated with either 400 nM of (-)JQ1 or (+)JQ1 
for 24 hours and then harvested for ChIP. BRD4 interacts with the AHNAK promoter and is 
displaced upon exposure to (+)JQ1. Significant differences: ns, nonsignificant, P > 0.05; *, P 




knockdown of BRD4, and not of BRD2 or BRD3 dramatically downregulated both  
AHNAK mRNA and protein expression (Fig. 2.5B-G; Fig. 2.6A and 2.6B). We then 
assessed if BRD4 associates with the AHNAK promoter by ChIP (43). We found that 
BRD4 interacts with the AHNAK promoter, and that treatment with (+)JQ1 disrupts this 
interaction (Fig. 2.6C). These results confirm that AHNAK is a BRD4 target gene, and 
that this relationship is conserved even in the absence of AR expression.  
BRD4-AHNAK signaling pathway regulates CRPC cell migration  
AHNAK promotes tumor metastasis and has previously been shown to regulate 
migration and invasion in DU 145 cells (41,44). We therefore hypothesized that AHNAK 
is critical for CRPC cell migration and invasion. To test this hypothesis, we first validated 
siRNA against AHNAK in each of our models (Fig. 2.7A, B, E, F, I and J ). Upon 
confirming depletion of AHNAK in each model, we then measured its effect on migration. 
Notably, knockdown of AHNAK by siRNA reduced migration in VCaP, 22Rv1 and DU 
145 cells by 38%, 43% and 33% respectively (Fig. 2.7C, G and K). Likewise, AHNAK-
depleted DU 145 cells had invasion reduced by 26% (Fig. 2.8A). Based on these results, 
we predicted that BRD4 acts upstream from AHNAK and regulates prostate cancer cell 
migration and invasion through a BRD4-AHNAK signaling pathway. We would then 
expect that the co-depletion of BRD4 and AHNAK would not further reduce migration. 
As expected, the co-depletion of BRD4 and AHNAK reduced migration in all models to 
levels comparable to depletion of either BRD4 or AHNAK alone (Fig. 2.7D, H and L). 
Furthermore, if BRD4 acts upstream of AHNAK, AHNAK overexpression in BRD4-
depleted cells should rescue cell migration. To test this hypothesis, we overexpressed 
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AHNAK in DU 145 cells (Fig. 2.8B and C) using a Flag-AHNAK plasmid (45,46). We 
found that overexpression of AHNAK increased migration in DU 145 cells by 23% in 
siRNA control cells (Fig. 2.8D). Significantly, overexpression of AHNAK rescued cell 
migration in BRD4-depleted cells (Fig. 2.8D). Together, these results identify AHNAK as 
a BRD4 target gene that regulates CRPC cell migration and invasion. 
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Figure 2.7. BRD4-AHNAK signaling pathway regulates CRPC cell migration. (A-
C) AHNAK relative mRNA expression measured in VCaP, 22Rv1 and DU 145 cells 72 hours 
after transfection with the indicated siRNAs (scramble; siAHNAK, 25 nmol/L). Bar represents 
means ± SEM of three independent experiments. Statistical analyses were performed using the 
Student’s t test. (D-F) Immunofluorescence images showing the expression of AHNAK in 
VCaP, 22Rv1 and DU 145 cells 72 hours after transfection with the indicated siRNAs 
(scramble; siAHNAK, 25 nmol/L). AHNAK is stained in red. Scale bar, 100 µm. 
Quantification of AHNAK immunofluorescence reflected as a percentage of relative 
fluorescence intensity (%RFI). Bar represents means ± SEM of individual cells (n ≥ 200 for 
all models). Results from two independent experiments are shown. Statistical analyses were 
performed using the Student’s t test. (G-L) VCaP, 22Rv1 and DU 145 cells were transfected 
with the indicated siRNAs (scramble; siBRD4, and siAHNAK 25 nmol/L or siBRD4 and 
siAHNAK 25 nmol/L) for 72 hours and then challenged for migration. Results are shown as a 
relative percentage of migration in comparison to scramble. Bar represents means ± SEM of 
three independent experiments. Statistical analyses were performed using the Student’s t test 
(F) and a one-way ANOVA (G). Significant differences: ns, nonsignificant, P > 0.05; *, P < 
0.05; **, P < 0.01; ***, p < 0.001). 
 
Figure 2.8. AHNAK knockdown inhibits DU 145 cell invasion and AHNAK 
overexpression rescues cell migration in BRD4-depleted cells. A, DU 145 cells were 
transfected with either control scramble or siAHNAK for 72 hours and then challenged for 
invasion using conditions described previously. Results are shown as a relative percentage of 
invasion in comparison to scramble. Representative images are shown as a percentage of 
invaded area in comparison to the total membrane area. Bar represents means ± SEM of three 
independent experiments. Statistical analyses were performed using the Student’s t test. 
Significant differences: *, P < 0.05. B, Flag-AHNAK expression validated by immunoblotting 
in DU 145 cells. Cells were infected with lentiviral particles containing either Vector or Flag-
AHNAK for 48 hours and selected for stable expression using media containing 1 µg/mL 
puromycin. C, Validation of AHNAK overexpression in DU 145 cells. Relative mRNA 
expression measured in Vector or Flag-AHNAK expressing cells. Statistical analyses were 
performed using the Student’s t test. D, DU 145 cells expressing either Vector or Flag-AHNAK 
were transfected with either scramble or siBRD4 for 72 hours and then challenged for 
migration. Results are shown as a relative percentage of migration in comparison to Vector + 
scramble. Representative images are shown as a percentage of migrated area in comparison to 
the total membrane area. Bar represents means ± SEM of three independent experiments. 
Statistical analyses were performed using a one-way ANOVA. Significant differences: ns, 




Selective degradation of BRD4 inhibits CRPC cell migration  
BET proteins can have individual, non-overlapping roles (28). JQ1 and BET 
degraders like ARV-771 lack intra-BET selectivity and leave open the possibility of off-
target effects in a therapeutic setting (17,22,27). Therefore, we tested whether MZ1, a 
novel small molecule BET degrader built on Proteolysis Targeted Chimeras (PROTAC) 
technology that has been shown to be BRD4 selective at low doses (30), could selectively 
degrade BRD4 and inhibit migration and invasion in our CRPC models. In control 
experiments, we confirmed that treatment of VCaP, 22Rv1 and DU 145 cells with low 
doses of MZ1 for 24 hours preferentially degraded BRD4 over BRD2 and BRD3 in all 
models (Fig. 2.9A, D and G) without affecting cell viability (Fig. 2.10A-C). Furthermore, 




cell migration and invasion to comparable levels produced by siRNA against BRD4  
(Fig. 2.9B, C, E, F, H and I; Fig. 2.10D). These results show that BRD4 can be 
selectively degraded in models of CRPC that differ greatly by aggressiveness and 




Figure 2.9. Selective degradation of BRD4 inhibits CRPC migration. (A-C) 
Immunoblot of BET protein expression in VCaP, 22Rv1 and DU 145 cells treated with the 
indicated doses of MZ1 for 24 hours. Quantifications relative to control (0.01% DMSO) with 
normalization using β-actin levels as a loading control are indicated. Red box indicates optimal 
dose for selective BRD4 degradation. Blots shown are representative of two independent 
experiments. (D-F) Immunofluorescence images showing the expression of BRD4 and 
AHNAK in VCaP, 22Rv1 and DU 145 cells after treatment with either 10 nM MZ1 (VCaP 
and 22Rv1) or 100 nM MZ1 (DU 145) for 24 hours. BRD4 is stained in green and AHNAK is 
stained in red. Scale bar, 100 µm. Quantification of BRD4 and AHNAK immunofluorescence 
reflected as a percentage of relative fluorescence intensity (%RFI).  Bar represents means ± 
SEM of individual cells (n ≥ 200 for all models). Results from two independent experiments 
are shown. Statistical analyses were performed using Student’s t test. (G-I) VCaP, 22Rv1 and 
DU 145 cells were pretreated with either 10 nM MZ1 (VCaP and 22Rv1) or 100 nM MZ1 (DU 
145) for 21 hours and then for 3 hours in serum free conditions. Cells were then challenged for 
migration under conditions described previously using a transwell system. Results are shown 
as a relative percentage of migration in comparison to control. Left panel: representative 
images of the total membrane area showing migrated cells stained with crystal violet. Right 
Panel: Bars represents means ± SEM of three independent experiments. Statistical analyses 





BRD4 and AHNAK expression associate with prostate cancer clinical parameters 
and biochemical recurrence-free survival  
Prostate cancer clinical parameters, a collection of measurements that determine 
tumor aggressiveness (Gleason Score) and stage (Tumor-Node-Metastasis), have been 
shown to associate with high biochemical-recurrence (BCR) rates, and together, are 
significant predicators of metastatic disease progression (47). Furthermore, BRD4 
expression has been shown to associate with prostate cancer patient outcomes and 
increase with castration resistance (48,49). Therefore, we tested the hypothesis that 
BRD4 and AHNAK are critical to the clinical progression of CRPC, and determined 
whether BRD4 and AHNAK expression correlate with prostate cancer clinical parameters 
and BCR-free survival. When comparing the expression of BRD4 to prostate cancer 
clinical parameters, there was a significant correlation in vivo to Gleason score (p = 
0.0089, Fig. 2.11A), pathological T (p = 0.028, Fig. 2.11B) and pathological N (p = 
0.0018, Fig. 2.11C). Interestingly, no significant correlation between these parameters 
and AHNAK expression was observed (data not shown). However, when comparing 
Figure 2.10. MZ1 at BRD4-selective concentrations does not affect cell viability 
and inhibits DU 145 cell invasion. (A-C) MTT assay showing the viability of VCaP, 
22Rv1 and DU 145 cells treated with either 10 nM MZ1 (VCaP and 22Rv1) or 100 nM MZ1 
(DU 145) for 24 hours. Results are shown as relative percentage of viability in comparison to 
control.  Bar represent means ± SEM of three independent experiments. Statistical analyses 
were performed using the Student’s t test. D, DU 145 cells were pretreated with either control 
(0.01% DMSO) or 100 nM MZ1 for 21 hours and then for 3 hours in serum free conditions. 
Cells were then challenged for invasion using conditions described previously. Representative 
images are shown as a percentage of invaded area in comparison to the total membrane area. 
Bar represents means ± SEM of three independent experiments. Statistical analyses were 





BRD4 and AHNAK expression, there was a significant correlation between the two 
genes (p = 1.5e-14, correlation coefficient = 0.33, Fig. 2.11D). Furthermore, data from a 
smaller 2015 study that performed whole exome sequencing from 150 mCRPC patients 
show a borderline significant correlation between BRD4 and AHNAK expression (Fig. 
Figure 2.11. BRD4 and AHNAK expression associate with prostate cancer clinical 
parameters and biochemical recurrence-free survival. (A-C) Correlation between 
BRD4 expression and Gleason score, pathological T and pathological N. Bar represents means 
± SEM (A) or means ± 95% CI (B and C) with number of individuals per parameter indicated. 
D, Comparison of BRD4 and AHNAK expression in 488 clinical samples by linear regression. 
Spearman rank correlation, p value and total number of individuals indicated. E, Kaplan-Meier 
curve of biochemical recurrence-free survival of 421 prostate cancer patients was calculated 
from the TCGA database. Patients were segregated into cohorts with ‘high expression’ 
(BRD4high and AHNAKhigh) and ‘low expression’ (BRD4low and AHNAKlow) and remaining 





Lastly, we performed 
a meta-analysis of 
421 patients with 
adenocarcinoma of 
the prostate using the 
TCGA repository, 
and determined that 




expression of BRD4 
and AHNAK were 
significantly associated 
with a shorter time to 
BCR in prostate cancer patients (Fig. 2.11E; HR = 2.38, log-rank p = 0.013). In 
summary, expression of BRD4 and AHNAK significantly influences clinical and 




Figure 2.12. BRD4 and AHNAK expression correlate in 
mCRPC patients. Comparison of BRD4 and AHNAK 
expression in 118 clinical samples by linear regression. Spearman 






Our work establishes that among the BET protein family, BRD4, but not BRD2 or 
BRD3, is the principal regulator of CRPC cell migration and invasion. Treatment of 
CRPC cells with JQ1, a pan-BET inhibitor, left open the possibility that each of BRD2, 
BRD3 and BRD4 were responsible for regulating CRPC cell migration in all models (Fig. 
2.1). Although previous studies have suggested that each BET family member is critical 
in mediating metastatic properties in cell line models of CRPC (22,24), we used BET-
selective siRNAs to prove that BRD4 alone is essential. We also provide evidence that 
suggests that the functional requirement for BET family members depends on AR status. 
BRD4 regulated cell migration across all models of CRPC, regardless of aggressiveness 
and AR status, whereas BRD2 and BRD3 only regulated migration in less aggressive 
models that retained AR expression or signaling (Fig. 2.2 and 2.3). These findings 
demonstrate once again that for a common biological function, each BET family member 
is capable of exerting its own independent function, while at the same time individual 
BET proteins are also capable of generating overlapping or even opposing effects (Fig. 
2.4B-D) (28).  
Because only BRD4 consistently regulated pro-metastatic properties in each of 
our models, we hypothesized that a common set of BRD4 target gene(s) exists, and that 
these target genes are critical for migration and invasion. In that pursuit, we identified 
AHNAK, a large scaffolding protein previously shown to contribute to cell migration and 
invasion in prostate cancer cells (41), as a BRD4 target gene in DU 145 cells (Fig. 2.5A). 
We then determined whether the BRD4-AHNAK relationship was unique to AR-null 
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CRPC cell models (Fig. 2.5F and 2.5G; Fig. 2.6A and 2.6B), or conserved across all 
CRPC models. A previous report showed that upon loss of AR, signaling networks that 
were prominent in AR-competent cells failed to play the same role in cells that were no 
longer dependent on AR-mediated transcription (10). Intriguingly, we discovered that 
AHNAK was a BRD4 target gene in all models (Fig. 2.5B-E), evidenced by BRD4 
interaction with AHNAK promoter chromatin (Fig. 2.6C), suggesting that this newly 
identified BRD4-AHNAK relationship is conserved regardless of AR status. This result 
stands apart to previous reports that BET family members directly interact with and 
regulate a set of AR target genes (25). AR signaling is known to control prostate cancer 
cell migration and invasion (52). Thus, it is likely that BET proteins regulate prostate 
cancer cell migration and invasion via at least two co-existing mechanisms: through AR 
signaling and through AHNAK. In AR signaling-proficient cells, BET proteins bind to 
AR and drive expression of several AR-dependent genes (25), including pro-metastatic 
genes. We have shown that the BRD4/AHNAK axis regulates migration and invasion in 
our models regardless of AR status. Therefore, BRD4 targeting would alter these two 
pathways concomitantly and dramatically impair cell dissemination. However, in AR-
deficient cells, the subsequent AR-dependent BET-mediated pathways driving migration 
and invasion are lost, thus the BRD4/AHNAK axis may become predominant. Because 
AHNAK was regulated by BRD4 in all models, it allowed us to determine its 
significance in cell migration and invasion. Consistent with this model, AHNAK was 
found to play a critical role in mediating cell migration and invasion in our models (Fig. 
2.7; Fig. 2.8A-D), reinforcing newly published results that establish AHNAK as a critical 
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mediator of tumor metastasis (44). In addition to its contribution to the development of 
pseudopodia (41), other reports have shown that AHNAK plays an integral role in both 
SMAD3 and RAF-MEK-ERK signaling, as an intermediary for these canonical signaling 
pathways (44,53). Based on these previous findings, we hypothesize that AHNAK serves 
dual roles in its regulation of CRPC cell dissemination. We suspect that it functions as a 
key structural component in the formation of pseudopodia which allows prostate cancer 
cells to protrude and induce invasive/migratory behavior, while also serving as a 
downstream effector for key signaling pathways that relay critical signals (i.e. 
chemokines and cytokines) from the tumor microenvironment. Each of these potential 
functions illustrates AHNAK’s significance to the larger process of CRPC dissemination 
and metastasis, and thus it is not surprising that the expression of both AHNAK and 
BRD4 correlate with critical prostate cancer clinical markers and BCR-free survival in 
prostate cancer patients (Fig. 2.11; Fig. 2.12). 
Treatment for patients with CRPC always includes a means to disrupt the 
androgen/AR axis, and while effective for an average of 2-3 years, ADT inevitably fails 
to impede progression due to the acquired resistance mechanisms that come as a result of 
AR adaptations (4). Because of this understanding, new therapies that go beyond directly 
targeting the AR to treat CRPC have begun to emerge, including a multitude of pan-BET 
inhibitors and degraders (22,54-56). While each of these new therapeutics have been 
shown to successfully inhibit or degrade the BET family of proteins, they lack intra-BET 
selectivity and have primarily been shown to only effectively regulate cell proliferation 
and viability in models of CRPC that retain AR expression. These results are misleading 
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because they give the false impression that targeting BET proteins is only viable in AR-
competent models of CRPC, yet the data outlined throughout this report shows that 
BRD4 retains functionality towards regulating pro-metastatic properties in models of 
CRPC that are both AR-competent and AR-deficient. As we and others have reported 
previously, the need for pan-BET inhibition or degradation is context and cancer 
dependent. BET proteins are not always functionally redundant, and because each family 
member regulates transcription in a unique way, investigators must first elucidate the 
relevant BET proteins for any specific biological function. Based on that principle, and 
the findings reported here in Fig 2.1-2.7, we selectively targeted BRD4 in each of our 





results obtained using siRNA against BRD4 (Fig. 2.9; Fig. 2.10D). MZ1 is a Proteolysis 
Targeted Chimeras (PROTAC) degrader, and has been shown to preferentially degrade 
BRD4 over BRD2 and BRD3 in certain cell lines (30). Whereas other PROTAC 
molecules like ARV-771 and dBET1/dBET2 appear to not discriminate among the BET 
family of proteins (22,54), crystallographic and biophysical studies have shown that the 
specific nature of the ternary complex formed by MZ1 with the E3 ligase VHL and the 
BRD4 bromodomain defines this BRD4 selectivity (57). Future studies will need to 
validate MZ1’s efficacy and selectivity in more advanced model systems, yet the work 
shown here (Fig. 2.13) provides a novel mechanism that could be targeted with therapies 








Figure 2.13. Visual overview depicting BRD4 regulation of CRPC cell migration 
and invasion. A, Graphical depiction of the different AR statuses represented in the CRPC 
cell lines from this study, and the corresponding functional BET proteins pertaining to 
regulating cell migration. The merging of the three cell types and the numbers that represent 
each type illustrate the AR heterogeneity that has been previously observed in multiple 
genomic studies of mCRPC tumors.  B, Graphic highlights BRD4 regulation of AHNAK 
transcription through its interaction with the AHNAK promoter, and how within each cell type, 
only BRD4 is capable of carrying out this process. AHNAK is then shown to facilitate 
migration and invasion through its ability to develop pseudopodia while also serving as a 
scaffolding protein for a variety of canonical signaling pathways that interact with factors 
secreted from the tumor microenvironment.  
 
C, Illustration showing MZ1 selectively binding too and degrading BRD4 through 
polyubiquitination and proteasome-dependent de radation. As a result, BRD4 is unable to 
recruit co-activator proteins to the AHNAK promoter and carry out transcription of AHNAK. 
Lack of AHNAK represses the cells mig atory and invasive capabiliti s and as a result cell 
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Progression from localized to metastatic castration resistant prostate cancer 
(mCRPC) occurs as a result of accumulated resistance mechanisms that develop upon 
sustained androgen receptor (AR) suppression. Critical to this progression is the plastic 
nature by which prostate tumor cells transition from epithelial to mesenchymal (EMT). 
Here, using prostate cancer cell lines with different AR composition, we systematically 
manipulated the bromodomain and ExtraTerminal (BET) proteins to determine which 
BET proteins influence EMT. We found that only BRD4 – and not BRD2 or BRD3 - 
regulates the expression of Snail and Slug, and that the downregulation of these 
transcription factors significantly increases E-Cadherin expression. Moreover, selective 
degradation of BRD4 with MZ1 ablates EMT (transcriptionally and morphologically) 
induced by TGFß signaling. Overall, these results identify a key EMT gene signature 







 Prostate cancer (PCa) is the most commonly diagnosed cancer in men and over 
90% of PCa-associated mortality is caused by the development of metastases (1,2). 
Second generation anti-androgen therapies abiraterone and enzalutamide (ADT) remain 
the standard of care for men with advanced prostate cancer and are initially quite 
effective in suppressing both androgen production and androgen receptor (AR) signaling, 
yet disease progression to castration-resistance prostate cancer (CRPC) remains 
inevitable (2,3). While resistance mechanisms that include AR gene amplification, gain-
of-function AR point mutations and complete loss of AR expression are critical for 
prostate tumor cells to overcome sustained AR suppression, emerging evidence suggests 
that the transition from an epithelial to mesenchymal state is an additional adaptive 
evolutionary response that creates an environment suitable for therapeutic resistance (4). 
The epithelial-mesenchymal transition (EMT) is a normal biological process 
active during embryogenesis that is often reactivated in cancer cells (2,5,6). Upon 
induction, non-motile epithelial cells break away from intracellular tight junctions and 
acquire a mesenchymal phenotype which creates a highly mobile and invasive cell 
(2,5,6). On a molecular level, EMT is initiated by several families of transcription factors, 
including Snail/Slug and ZEB1/2, which repress the expression of E-Cadherin and other 
epithelial genes by docking to several E-boxes in the promoter region (2,5,6). Recent 
studies demonstrated that derepression of Snail is an adaptive response to AR inhibition 
and is a critical resistance mechanism in CRPC (4,7). Therefore, the discovery of 
druggable targets that work by suppressing EMT mediators such as Snail, irrespective of 
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AR status, are highly desirable. 
Bromodomain and ExtraTerminal (BET) family of proteins (BRD2, BRD3, 
BRD4 and testis-specific BRDT), are epigenetic readers that bind to specific acetylated 
lysine residues in histones as a means to regulate gene transcription (8). Having been 
identified as key contributors to the progression of B-cell lymphoma, lung, breast, 
pancreatic and prostate cancers, intense efforts have been spent towards developing 
multiple small molecule pan-BET inhibitors and degraders (8). While pan-BET therapies 
such as JQ1 and ARV-771 have shown promising results in variety of cancer models, 
including CRPC (9,10), evidence continues to suggest that the need for a pan-BET 
approach is dependent upon the context and the cancer. As we have shown on multiple 
occasions in a variety of breast and prostate cancer models, BET proteins modulate 
distinct signaling pathways, including those that regulate EMT, and can even have non-
overlapping and opposing functions (11-13). Here, we followed up from our previous 
findings which showed that only BRD4, and not BRD2 or BRD3, regulates CRPC 
dissemination, to show that BRD4 regulates a key gene signature critical for the induction 





MATERIALS AND METHODS 
Cell Culture 
 Human prostate cancer cell lines maintained at the NCI Office of Physical 
Sciences-Oncology centers (PS-OC) Network Bioresource Core Facility (PBCF) were 
contractually obtained through the American Type Culture Collection, under a Material 
Transfer Agreement. The cell lines have been authenticated by the NIH Physical Sciences 
Oncology Consortium.  22Rv1 and DU 145 prostate cancer cell lines were cultured in 
RPMI-1640 medium (Gibco). VCaP prostate cancer cells were cultured in DMEM 
medium (Gibco). All culture media were supplemented with 10% fetal bovine serum 
(FBS, Corning) and 1% antibiotics (penicillin/streptomycin, Gibco). Cell lines were 
grown at 37°C in 5% CO2. Mycoplasma contamination was prevented by treating cells 
with plasmocin (5 µg/mL for 2 weeks, Invivogen) after thawing and prior to experiments.  
Antibodies and Reagents 
The following antibodies were used: anti-BRD2, BRD3 and BRD4 (Bethyl 
Laboratories), anti-Snail, anti-Slug, anti-E-cadherin, anti-Smad3, anti-β-Actin (Cell 
Signaling) and anti-p-Smad3 (Abcam). HRP-conjugated secondary antibodies were 
purchased from Bio-Rad. Fluorochrome-conjugated secondary antibodies were obtained 
from Jackson Laboratories. The inactive JQ1 enantiomer (referred to as ‘control’), active 
JQ1 (‘JQ1’), and MZ1 were purchased from Tocris. 0.01% DMSO was used as control 
for MZ1 experiments. Recombinant human TGFß was purchased from R&D systems.  
Plasmids, siRNAs and Transfection 
Lentivirus-mediated eGFP-BRD4 expressing plasmid (EX-E0102-Lv122) and 
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control vector (EX-NEG-Lv242) were purchased from GeneCopoeia. HEK-293 cells 
were co-transfected with plasmids encoding for VSV-G, dR8.2 dvpr and either eGFP-
BRD4 or control plasmid using Lipofectamine 2000 reagent (Thermo Fischer Scientific). 
Viral supernatants were collected, and together with 4 µg/mL Polybrene (Millipore), 
were used to infect 22Rv1 and DU 145 cells for 48 hours. Stable clones were selected 
using medium containing 1 µg/mL puromycin (Invivogen). ON-Targetplus Human BET 
and Non-Targeting (scramble) SMARTpool siRNAs were purchased from Dharmacon. 
Cells were transfected with 25 nmol/L of listed siRNA for 72 hours with Lipofectamine 
2000. 
Immunoblotting 
Cell pellets were lysed in RIPA buffer (50 mmol/L Tris/HCl pH 7.5, 1 mmol/L 
EDTA, 0.5 mmol/L EGTA, 150 mmol/L NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 
1% Triton X-100). Samples containing 25 µg of protein were resolved by SDS-PAGE 
and transferred to nitrocellulose membranes. Membranes were saturated in TBS-BSA 5% 
to block non-specific binding sites, probed with primary antibodies and then visualized 
with HRP-conjugated secondary antibodies. Upon incubation in ECL, membranes were 
quantified with a gel imager. 
qRT-PCR 
Total RNA was extracted using the RNAeasy Kit (Qiagen). Reverse transcription 
reactions were performed with 1 µg of total RNA with the QuantiTect Reverse 
Transcription kit (Qiagen). The following genes were detected using the corresponding 
primers that were first checked for specificity with BLAST: SNAI1 (forward: 5’-
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ACCACTATGCCGCGCTCTT-3’, reverse: 5’-GGTCGTAGGGCTGCTGGAA-3’), 
SNAI2 (forward: 5’-TGTTGCAGTGAGGGCAAGAA-3’, reverse: 5’-
GACCCTGGTTGCTTCAAGGA-3’), CDH1 (forward: 5’-
AGAGGACCAGGACTTTGACTTG-3’, reverse: 5’-CAGAGAATCATAAGGCGGGG-
3’); the mean expression of the following housekeeping genes were used to normalize the 
results: ACTB (forward: 5’-ATTGGCAATGAGCGGTTCC-3’, reverse: 5’-
GGTAGTTTCGTGGATGCCACA-3’), YWHAZ (forward: 5’-
ACTTTTGGTACATTGTGGCTTCAA-3’, reverse: 5’-
CCGCCAGGACAAACCAGTAT-3’). PCR amplifications were performed with MESA 
Green qPCR MasterMix (Eurogentec) on an ABI Prism 7500 thermal cycler. 
Chromatin Immunoprecipitation 
The ChIP-seq dataset GSE55062 (14) was taken from the NCBI Gene Expression 
Omnibus database and visualized using Integrative Genomics Viewer (IGV (15)). 
Immunocytochemistry  
Cells were fixed in absolute methanol for 5 minutes at - 20°C and then 
permeabilized with PBS, 0.2% Triton X-100 buffer for 10 minutes. After saturation in 
blocking buffer (0.02% Triton X-100, 2% BSA in PBS) for 30 minutes, permeabilized 
cells were incubated with primary antibodies and then fluorochrome-conjugated 
secondary antibodies (diluted in blocking buffer) for 1 hour. Lastly, coverslips were 
mounted with ProLong Gold with DAPI (Thermo Fischer Scientific). Image acquisition 
was conducted using a Leica DM IL LED inverted microscope. Fluorescence intensities 
were determined using ImageJ software (NIH). Intensities were measured from 
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individual cells, corrected for background signal, and normalized by cell area.  
Flow Cytometry 
 Single cell suspensions were washed after collection and stained in ice-cold 
Ca2+/Mg2+ -free PBS with a viability dye (Zombie NIR, BioLegend) for 20 minutes at 4 
°C in the dark. Cell suspensions were then washed twice with ice-cold flow cytometry 
buffer (Ca2+/Mg2+ -free PBS, supplemented with 2% FBS and 2mM EDTA), fixed for 
intracellular staining (eBioscience Intracellular Fix and Perm Set, Invitrogen), and stained 
with the appropriate antibody (listed in Supplementary Table S1) for 20 minutes at room 
temperature in the dark. All cell suspensions were washed twice in ice-cold flow 
cytometry buffer prior to analysis. Unstained cells and single-stained controls were used 
to calculate compensation. Data acquisition was performed on BD LSRII at the Boston 
University Flow Cytometry Core Facility. Data analysis was carried out using FlowJo 
Software (version 10.6.1, Tree Star). 
Kaplan-Meier Analysis 
To investigate the correlation between biochemical recurrence-free survival 
(BCR), progression free survival (PFS) and BRD4, SNAI1, SNAI2 and CDH1 expression, 
we utilized data from 414 (BCR) and 488 (PFS) prostate cancer patients from the TCGA 
repository. The normalized expression values of the RNAseq ID 23476 (for BRD4), 6615 
(for SNAI1), 6591 (for SNAI2) and 999 (for CDH1) were used. For each gene, cutoff 
values were determined separately as described previously (16). In order to assess the 
potential additive effects of the genes, samples with high BRD4, high SNAI1, high SNAI2 
and low CDH1 were combined into one cohort and samples with low BRD4, low SNAI1, 
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low SNAI2 and high CDH1 were combined into a second cohort. CDH1 had an inverse 
correlation to survival compared to the other genes, therefore, when combining, we used 
its inverse expression not to eliminate the difference between the samples. Cox regression 
was used to compare the length of survival of the cohorts and a Kaplan-Meier plot was 
drawn to visualize the difference. Hazard ratio (HR) and p value are shown for 
biochemical recurrence-free survival and progression free survival by comparing the 
BRD4high, SNAI1high, SNAI2high and CDH1low and the BRD4low, SNAI1low, SNAI2low and 
CDH1high cohorts. Finally, we used the patient samples to directly compare BRD2 or 
BRD3 or BRD4 expression against SNAI1 and SNAI2 expression by drawing a linear 
regression and computing Spearman rank correlation coefficients. The gene expression 
data and survival times are listed in Supplementary Tables S2 and S3. 
Statistical Analysis 
Statistical analyses of the in vitro experiments were performed using Student’s t 
test or ANOVA as indicated, and were generated by GraphPad Prism software. p < 0.05 





BRD4 regulates critical EMT gene signature 
We previously established that BRD4 plays a significant role in the regulation of 
CRPC cell migration and invasion (13). As part of that work we profiled 73 genes 
involved in pathways important for EMT, and discovered that knockdown of BRD4 
significantly downregulated the expression of AHNAK (13). In addition to AHNAK, the 
findings also suggested that multiple transcription factors known to facilitate 
transcriptional programs critical for EMT, including members of the Snail family 
(SNAI1/Snail and SNAI2/Slug), were under BET-protein control (13). To investigate 




H874Y) and  DU 145 (AR-null) and cells for 24 hours with the pan-BET inhibitor JQ1 
(Fig. 3.1A and 3.1E). We found that JQ1 treatment led to the significant downregulation 
of both Snail and Slug. Interestingly, we also found that pan-BET inhibition caused a 
slight reduction in the expression of E-Cadherin in both cell lines. Snail and Slug are 
zinc-finger transcription factors and work to induce EMT by repressing the expression of 
adhesion molecules like E-Cadherin (2,5,6). Therefore, we considered that pan-BET 
inhibition may obscure the influence that each BET protein has on regulating EMT. To 
resolve this, we measured the mRNA and protein expression of Snail, Slug and E-
Cadherin upon depletion of either BRD2, BRD3 and BRD4 in 22Rv1, DU 145 and VCaP 
(AR-WT/Amp) cells (Fig. 3.1B and 3.1F; Fig. 3.2A-C). In all three cell lines, the 
knockdown of only BRD4 – and not of BRD2 or BRD3 – significantly reduced the 
expression of Snail and Slug at both the mRNA and protein level. Intriguingly, E-
Cadherin expression was significantly increased at the mRNA (VCaP and DU 145) and 
protein level (DU 145) upon BRD4 depletion, yet only marginally increased under the 
same conditions in 22Rv1 cells. To further determine whether BRD4 regulates this EMT 
Figure 3.1. BRD4 regulates critical EMT gene signature. A and E, Protein expression 
of BET proteins: BRD2, BRD3 and BRD4, EMT transcription factors: Snail and Slug and 
EMT marker: E-Cadherin in 22Rv1 and DU 145 cells after being treated with either 400 nM 
of (-)JQ1 or (+)JQ1 for 24 hours. Blots shown are representative of two independent 
experiments. B and F, Validation of BET depletion by siRNA (25 nmol/L for 72 hours) and 
protein expression of Snail, Slug and E-Cadherin in 22Rv1 and DU 145 cells. Blots shown are 
representative of three independent experiments. C and G, Validation of BRD4 
overexpression and protein expression of Snail, Slug and E-Cadherin in 22Rv1 and DU 145 
cells. Blots shown are representative of three independent experiments. D and H, Protein 
expression of BET proteins: BRD2, BRD3 and BRD4, EMT transcription factors: Snail and 
Slug and EMT marker: E-Cadherin in 22Rv1 and DU 145 cells after being treated with either 
0.01% DMSO (control), 10 nM (22Rv1) or 100 nM (DU 145) MZ1 for 24 hours. Blots shown 




gene signature, we overexpressed BRD4 in 22Rv1 and DU 145 cells (Fig. 3.1C and 
3.1G). Importantly, we found that overexpression of BRD4 in each cell line dramatically 
increased the expression of Snail and Slug and likewise significantly reduced the 
expression of E-cadherin (Fig. 3.1C and 3.1G; Fig. 3.3A and 3.3B). These data support 

























(PROTAC) technology (17), could repress Snail and Slug while enhance E-Cadherin 
expression (Fig. 3.1D and 3.1H). As predicted, treatment of 22Rv1 and DU 145 cells 
with a BRD4-selective dose of MZ1 for 24 hours reduced the expression of both Snail 
and Slug and modestly increased the expression of E-Cadherin. Collectively, these results 
identify BRD4, and not BRD2 or BRD3, as a key transcriptional regulator of EMT, and 
once again illustrates how the use of pan-BET inhibitors can obscure BET protein 
functionality. 
Selective degradation of BRD4 represses TGFß induced EMT 
 The induction of EMT in tumor cells is thought to primarily occur through the 
uptake of secreted soluble factors from nearby stromal cells leading to the activation of 
tumor cell signaling pathways/EMT transcriptional mediators (2,5,6). Transforming 
Figure 3.2. BRD4 regulates SNAI1, SNAI2 and CDH1 in 
multiple CRPC cell lines. (A-C) Relative mRNA expression of 
SNAI1, SNAI2 and CDH1 in control scramble or BET depleted 
VCaP, 22Rv1, and DU 145 cells. Bar represents means ± SEM 
of three independent experiments. Statistical analyses were 
performed using a one-way ANOVA. Statistical analyses were 
performed using a one-way ANOVA. Significant differences: 





growth factor ß (TGFß) is a multifunctional cytokine that is characterized as a strong 
promoter of EMT and metastases in advanced prostate cancer (2,18). To determine 
whether BRD4 maintains its ability to regulate EMT in the presence of TGFß, we 
measured the expression of Snail and Slug in DU 145 and 22Rv1 cells treated with either 
TGFß, MZ1 or MZ1 + TGFß (Fig. 3.4A and Fig. 3.5A). Cells stimulated with TGFß for 
24 hours showed a significant increase in Snail and Slug expression. More importantly,  
 
Figure 3.3. Overexpression of BRD4 significantly reduces E-Cadherin expression 
in 22Rv1 cells. A, Flow cytometry experimental design and gating strategy to analyze E-
Cadherin expression in 22Rv1 cells expressing vector or eGFP-BRD4. Schematic shown is 
representative of two independent experiments. B, 22Rv1 cells expressing either control vector 
or eGFP-BRD4 were analyzed for E-Cadherin expression. The histograms represent the 
quantification of the illustrated flow cytometry curves. Error bars represent SEM of two 
independent experiments. Statistical analyses were performed using the Student’s t test. 





loss of BRD4 as a result of MZ1 treatment prevented the increase of Snail and Slug that 
was observed upon TGFß stimulation. These results suggested that BRD4 may directly 
regulate signaling at the receptor level by mediating the activation of Smad3. Likewise, 
Snail and Slug have previously been shown to be targets of EMT induced through TGFß-
Smad3 signaling in prostate cancer (5,19). To test this hypothesis, we measured the 
phosphorylation of Smad3 in DU 145 cells treated with MZ1 and dosed with TGFß (Fig. 
3.4B). Degradation of BRD4 had no effect on Smad3 phosphorylation at either 30  
Figure 3.4. Selective degradation of BRD4 represses TGFß induced EMT. A, 
Protein expression of Snail and Slug in DU 145 cells after being treated with either 
0.01% DMSO, 5 ng/mL TGFß, 100 nM MZ1 or 5 ng/mL TGFß + 100 nM MZ1 for 24 
hours. Blots shown are representative of three independent experiments. B, 
Immunoblot of phospho-Smad3 (pSmad3) and Smad3 in DU145 cells treated with 
either 0.01% DMSO or 100 nM MZ1 for 21 hours, serum starved for 2 hours under the 
same conditions and then dosed with 5 ng/mL TGFß for the indicated time. The ratio 
of pSmad3:Smad3 illustrates Smad3 activation and quantifications are relative to 
control. Blots shown are representative of two independent experiments. C, 
Immunofluorescence images showing the expression of E-Cadherin in DU 145 cells 
after  being treated with either 0.01% DMSO, 5 ng/mL TGFß, 100 nM MZ1 or 5 ng/mL 
TGFß + 100 nM MZ1 for 24 hours. E-Cadherin is stained in red and nuclei is stained 
in blue with DAPI in the merged images (lower panels). Scale bar, 100 µm. 
Quantification of E-Cadherin immunofluorescence reflected as a percentage of relative 
fluorescence intensity (%RFI). Bar represents means ± SEM of individual cells (n ≥ 
350 in all conditions). Results from two independent experiments are shown. Statistical 
analyses were performed using a one-way ANOVA. Significant differences: ns, 





minutes or 1 hour of TGFß stimulation compared to control cells, implying that the  
regulation exerted by BRD4 occurs directly at the promoter region of SNAI1 and SNAI2. 
To corroborate this, we probed a public repository for ChIP-sequencing data on BRD4 in 
VCaP cells (GSE55062 (14)). BRD4 was detected with RNA Pol II at the promoters for 
SNAI1 and SNAI2, and notably was displaced upon JQ1 treatment (Fig. 3.6A and 3.6B). 
Next, we immunostained DU 145 and 22Rv1 cells to measure E-Cadherin and detect any 
morphological/phenotypical changes under the aforementioned conditions (Fig. 3.4C and 
Fig. 3.5B). DU 145 cells are characterized as epithelial and cuboidal in shape (20), and 
when grown as a monolayer they express moderate levels of E-Cadherin at tight junctions 
as shown in the control cells. As expected, TGFß treated cells had reduced expression of 
E-Cadherin, coupled with a flatter, more spindle-like cell consistent with a mesenchymal 
phenotype. Alternatively, cells treated with MZ1 had a significant increase of E-Cadherin 
expression along tight junctions, as observed by their enhanced cuboidal shape. 
Critically, cells treated with both MZ1 and TGFß maintained their cuboidal shape, 
indicating that the degradation of BRD4 conserves the expression of  
Figure 3.5. MZ1 ablates TGFß induced EMT in 22Rv1 cells. A, Protein expression 
of Snail and Slug in 22Rv1 cells after being treated with either 0.01% DMSO, 5 ng/mL 
TGFß, 10 nM MZ1 or 5 ng/mL TGFß + 10 nM MZ1 for 24 hours. Blots shown are 
representative of two independent experiments. B, Immunofluorescence images 
showing the expression of E-Cadherin in 22Rv1 cells after  being treated with either 
0.01% DMSO, 5 ng/mL TGFß, 10 nM MZ1 or 5 ng/mL TGFß + 10 nM MZ1 for 24 
hours. E-Cadherin is stained in red and nuclei is stained in blue with DAPI in the 
merged images (lower panels). Scale bar, 100 µm. Quantification of E-Cadherin 
immunofluorescence reflected as a percentage of relative fluorescence intensity 
(%RFI). Bar represents means ± SEM of individual cells (n ≥ 100 in all conditions). 
Results from two independent experiments are shown. Statistical analyses were 
performed using a one-way ANOVA. Significant differences: ns, nonsignificant, P > 





Figure 3.6. BRD4 binds at the SNAI1 and SNAI2 locus in VCaP cells. (A-
B) Publicly available ChIP-seq datasets performed on DHT or DHT + JQ1-treated 
VCaP cells231 were analyzed for the binding of BRD4 and RNA Pol II at the SNAI1 
and SNAI2 locus. The analyzed datasets are accessible on the GEO platform 





E-Cadherin even in the presence of TGFß. Taken together, these results indicate that 
BRD4 mediates TGFß-Smad3 signaling targets at the transcriptional level, and that 
degradation of BRD4 successfully prevents the transition of PCa cells from an epithelial 
state to a mesenchymal state.   
BRD4 expression correlates with EMT gene signature and survival outcomes in 
prostate cancer patients 
The individual expression of BRD4, Snail, Slug and E-Cadherin have all 
previously been shown to independently associate with prostate cancer disease states and 
patient outcomes (21-23). Since we determined that BRD4, and not BRD2 or BRD3 
expression correlates with Snail, Slug and E-Cadherin in our cell lines, we considered 




patients and likewise influence survival outcomes. Using the TCGA repository, we 
compared the expression of BRD2, BRD3 and BRD4 to SNAI1 and SNAI2 and found that 
only BRD4 had a positive correlation with these genes (Fig. 3.7A and Fig. 3.8A (24)). 
Next, we performed a meta-analysis of 414 (BCR) and 488 (PFS) patients with 
adenocarcinoma of the prostate, and determined that BRD4, SNAI1, SNAI2 and CDH1 
expression correlates with BCR-free survival and Progression-free survival (Fig. 3.7B  
Figure 3.7. BRD4 expression correlates with EMT gene signature and survival 
outcomes in prostate cancer patients. A, Comparison of BRD2, BRD3, BRD4 and SNAI1 
expression in prostate cancer patient clinical samples by linear regression. Spearman rank 
correlation, p value and total number of individuals indicated. B, Kaplan-Meier curve of 
biochemical recurrence-free survival and progression free survival of 414 (BCR) and 488 (PFS) 
prostate cancer patients was calculated from the TCGA database. Patients were segregated into 
cohorts with ‘low expression’ (BRD4low, SNAI1low, SNAI2low and CDH1high) and ‘high 






and Fig. 3.8B). High expression of BRD4, SNAI1, SNAI2 and low expression of CDH1 
significantly associated with a shorter time to BCR in prostate cancer patients (HR = 
1.72, log-rank p = 0.047). Likewise, the same expression profile correlated with time to 
PFS (HR = 1.95, log-rank p = 0.0019). Notably, when substituting either BRD2 or BRD3 
for BRD4, or when removing the BET proteins altogether from this gene signature, the 
expression profile no longer significantly associated with time to BCR (Fig. 3.8B). In 
total, these results strongly suggest that the expression of BRD4, but not BRD2 or BRD3, 
significantly correlates with this EMT gene signature and dramatically influences 
survival outcomes in prostate cancer patients. 
 
  
Figure 3.8. BRD2 and BRD3 expression does not correlate with EMT gene 
signature or BCR in prostate cancer patients. A, Comparison of BRD2, BRD3, BRD4 
and SNAI2 expression in prostate cancer patient clinical samples by linear regression. Spearman 
rank correlation, p value and total number of individuals indicated. B, Kaplan-Meier curves of 
biochemical recurrence-free survival of 413 prostate cancer patients was calculated from the 
TCGA database. Patients were segregated into cohorts with ‘low expression’ (SNAI1low, 
SNAI2low and CDH1high), (BRD2low, SNAI1low, SNAI2low and CDH1high) or (BRD3low, SNAI1low, 
SNAI2low and CDH1high) and ‘high expression’ (SNAI1high, SNAI2high and CDH1low),  (BRD2high, 
SNAI1high, SNAI2high and CDH1low) or (BRD3high, SNAI1high, SNAI2high and CDH1low). Hazard 





Our results demonstrate that BRD4, and not BRD2 or BRD3, positively regulates 
key transcriptional mediators of EMT in multiple prostate cancer cell lines of varying AR 
composition (Fig. 3.1-3.3). These findings build upon and support our previous work 
which showed that selective targeting of BRD4 dramatically impedes prostate cancer cell 
migration and invasion (13). The discoveries outlined throughout this study were realized 
only after knocking down each BET family member, as treatment of PCa cells with JQ1 
revealed a critically different EMT expression profile (Fig. 3.1A, B, E and F). Whereas 
silencing or overexpressing  BRD4 reduced/enhanced the expression of Snail and Slug, 
and conversely enhanced/reduced the expression of E-Cadherin, JQ1 consistently 
downregulated the expression of all three genes (Fig. 3.1A, B, C, E, F and G). These 
results imply that the collective inhibition of BRD2, BRD3 and BRD4 turns on or off 
multiple off-target transcriptional networks, given that multiple studies have previously 
shown that E-Cadherin expression is inversely correlated with Snail and Slug expression 
(2,4,5). This concept was confirmed when treating cells with MZ1 produced a 
comparable EMT expression profile to cells that were treated with siRNA specific to 
BRD4 (Fig. 3.1D and 3.1H). 
Because MZ1 phenocopied the EMT expression profile that was generated when 
using siRNA against BRD4, we were determined to see whether MZ1 could prevent PCa 
cells from transitioning to a mesenchymal state when exposed to conditions that mimicked 
the tumor microenvironment (Fig. 3.4 and Fig. 3.5 (2,18)). Remarkably, MZ1 blocked 
Snail and Slug expression from increasing in TGFß stimulated PCa cells (Fig. 3.4A and 
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Fig. 3.5A). We followed up on this and confirmed that BRD4’s regulation most likely 
occurs at the transcriptional level, given that the loss of BRD4 did not impact Smad3 
activation (Fig. 3.4B and Fig. 3.6). This result was unexpected given that we previously 
showed that BRD4 directly regulates AHNAK, and AHNAK has been shown to serve as a 
necessary scaffolding protein for TGFß-Smad3 phosphorylation (25). Moreover, we also 




TGFß-treated PCa cells from losing their epithelial morphology (Fig. 3.4C and Fig. 3.5B). 
Therefore, we now speculate that the loss of BRD4 disengages key transcriptional 
machinery at BRD4-specific promoters, many of which directly influence EMT, including 
SNAI1, SNAI2 and AHNAK. This disruption enhances certain epithelial markers such as E-
cadherin, which shifts the cell into an elevated epithelial state and severely impairs cell 
motility and invasiveness (13).  
Finally, we also show that only BRD4 correlates with SNAI1 and SNAI2 expression 
as well as survival outcomes in patients with advanced prostate cancer (Fig. 3.7A and 3.7B; 
Fig 3.8A and 3.8B). The BRD4-SNAI1 relationship is likely critical for EMT and 
metastasis across diverse malignancies (26), as recently reported for gastric (27) and lung 
cancers (28). Our findings illustrate once again what a significant of a role BRD4 has 
compared to BRD2 and BRD3 in the context of prostate cancer disease progression. Yet, 
the overwhelming majority of BET protein therapeutics that are in clinical trials, including 
studies that have mCRPC patients, are pan-BET inhibitors (29). Considering the functional 
opposition of BRD2 and BRD4 in other transcriptional contexts important for EMT, such 
as ER+ breast cancer, pan-BET inhibitors carry unappreciated dangers in cancer clinical 
Figure 3.9. Visual overview of BRD4 role in regulating EMT in CRPC. A, Graphic 
highlights BRD4 regulation of Snail and Slug transcription through its interaction with these 
genes’ promoter. Snail and Slug are shown to repress CDH1 transcription by docking at the 
promoter, causing a reduction in E-cadherin expression. Loss of E-cadherin induces EMT and 
creates a highly mobile and invasive cell B, Illustration showing MZ1 selectively binding too 
and degrading BRD4 through polyubiquitination and proteasome-dependent degradation. As a 
result, BRD4 is unable to recruit co-activator proteins to the promoter of Snail and Slug and 
carry out transcription. Lack of Snail and Slug enables CDH1 transcription, resulting in an 





trials (30). Our findings (Fig. 3.9) underscore the need for targeted BRD4-selective small 
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 Rethinking In Vitro modeling of CRPC 
 Progression from localized prostate cancer to mCRPC occurs as a result of 
accumulated AR-related resistance mechanisms (1). These mechanisms include, but are 
not limited to: aberrant androgen synthesis, AR gene amplifications, AR mutations, 
production of constitutively active AR splice variants and alternative steroid receptors (1-
3). Though the vast majority of mCRPC tumors remain as adenocarcinomas and have 
robust AR expression and or signaling, recent translational studies reported that a 
substantial number of mCRPC tumors progressing on ADT no longer expressed AR or 
relied on AR signaling (4,5). These findings, which identified 5 distinct mCRPC 
phenotypes based on well-defined AR and neuroendocrine (NE) genes – AR high 
(ARPC), AR low (ARLPC), co-expression of AR and NE genes (AMPC), double 
negative i.e., AR-Null and NE-Null (DNPC) and small cell/NE high without AR 
(SCNPC) – further validate prior concerns from the scientific community that long-term 
use of AR inhibitors could increase the prevalence of AR-Null or AR signaling-
indifferent prostate tumor cells (4,6).  
Yet, as investigators continue to validate BET proteins as targets for treating 
mCRPC, the methods for doing so still predominately rely on using AR-signaling-
competent CRPC cell lines (7). While it remains unrealistic for any basic science study to 
use models that encompass all subtypes of translationally relevant AR-driven resistance 
mechanisms, and likewise, was logical for initial studies to emphasize the use of AR-
competent CRPC cell lines over AR-null models when first evaluating BET proteins as 
potential targets (8), to continue to do so ignores the heterogenic reality of the disease. 
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Prostate tumor cells undergo clonal selection in response to ADT (6), and thus, the 
likelihood that the evolution of resistance shifts away from AR-mediated signaling is 
high. Therefore, to more accurately investigate how individual BET proteins contribute to 
CRPC dissemination, we used prostate cancer cell lines that model both AR-competent 
and AR-incompetent mCRPC phenotypes (Fig. 2.1A). 
BRD4 regulates CPRC dissemination irrespective of AR status  
 Over 90% of prostate cancer-associated mortality is caused by the development of 
metastases (9,10). Furthermore, we previously established that BRD4 is a viable target 
for inhibiting triple-negative breast cancer dissemination (11), and in the context of 
prostate cancer dissemination, prior studies that utilized AR-competent models of CRPC 
suggested that each BET family member is critical in mediating metastatic properties 
(8,12,13). Thus, to better understand how BET proteins regulate CRPC dissemination, we 
measured CRPC cell migration across all models of CRPC upon knocking down each 
individual BET protein. While our findings corroborated prior studies that demonstrated 
that each of BRD2, BRD3 and BRD4 regulate CRPC cell migration and invasion in cell 
lines that express wild-type/Amplified AR, that was not the case in models of CRPC that 
express either a mutant form of AR (only BRD2 and BRD4) or no AR at all (only BRD4) 
(Fig. 2.2A-C). Though one might argue that these findings do not provide a strong 
enough rationale to avoid JQ1, as individual knockdown partially phenocopied the pan-
BET inhibitor, we also discovered that in a second, more aggressive AR-null model (PC-
3), depletion of BRD2 opposed the effects of BRD4 and actually enhanced a metastatic 
phenotype (Fig. 2.4D). These findings illustrate once again how each BET family 
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member is capable of exerting its own independent function and why it is critical to use 
the aforementioned, isoform-selective approach in a variety of CRPC models when trying 
to establish how to best target a family of transcriptional regulators that contain near 
identical homology. 
AHNAK is a BRD4-target gene required for CRPC cell migration and invasion 
 Since only BRD4 regulated metastatic properties in each of the tested models, we 
hypothesized that a common set of BRD4 target gene(s) exists and that these target genes 
are critical for migration and invasion. To identify potential BRD4-target genes important 
for prostate cancer cell migration and invasion, we carried out a gene expression analysis 
in BET protein-depleted DU 145 cells. By doing so, we identified AHNAK, a large 
scaffolding protein previously shown to contribute to cell migration and invasion in 
prostate cancer cells (14) (Fig. 2.5A). We then determined that this BRD4-AHNAK 
relationship was conserved across all CRPC models and required for CRPC cell 
migration and invasion (Fig. 2.5B-G; Fig. 2.6; Fig. 2.7 and Fig. 2.8A-D). This finding 
was particularly significant because a previous report showed that upon loss of AR, 
signaling networks that were once prominent in AR-competent cells failed to play the 
same role in cells that were no longer dependent on AR-mediated transcription (4). 
Therefore, we think it is likely that BET proteins, and in particular BRD4, regulate 
prostate cancer cell migration and invasion via at least two co-existing mechanisms: 
through AR signaling and through AHNAK. Lastly, we also discovered that the BRD4-
AHNAK relationship is translationally significant in that it exists in patients with prostate 
cancer, and high expression of both genes correlates with biochemical-recurrence free 
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survival (Fig. 2.11 and Fig. 2.12).  
BRD4, and not BRD2 or BRD3, regulates gene signature that drives EMT in CRPC 
 We followed up on our work that established BRD4 as the principal BET protein 
responsible for mediating CRPC cell migration and invasion (Fig. 2.13) by taking a 
closer look at how BET proteins regulate EMT. Our rationale for taking this approach 
was based in part on recent studies that demonstrated that a byproduct of AR suppression 
is reactivation of EMT (15,16), and that we previously showed that BRD2 and BRD4 
work in opposition of each other for regulating EMT in breast cancer (17). Furthermore, 
although the evidence supporting AHNAK as a vital driver of prostate cancer recurrence 
and dissemination was strong, we also believed that the metastatic phenotypes that we 
observed likely came as a result of changes to transcriptional programs on a much 
broader scale. To investigate this concept, we first measured the expression of Snail and 
Slug under JQ1 treatment. We chose to look at these genes given that these transcription 
factors directly repress E-cadherin expression and have previously been implicated in 
prostate cancer progression (16,18-20). Inhibition of BRD2, BRD3 and BRD4 led to the 
downregulation of both transcription factors, however it also led to the downregulation of 
E-cadherin (Fig. 3.1A and 3.1E). This finding was not expected given that Snail and Slug 
operate as parts of the transcriptional machinery that works to inhibit E-cadherin (CDH1) 
expression, and likewise, their own expression is typically inversely correlated with E-
cadherin (9,17,19,21). We felt JQ1 was likely activating or repressing a multitude of 
transcriptional programs that directly or indirectly effect EMT, thus obscuring how each 
BET protein contributes to this biological process. To overcome this uncertainty, we 
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measured the mRNA and protein expression of Snail, Slug and E-cadherin upon 
depletion of either BRD2, BRD3 and BRD4 in each of our CRPC models (Fig. 3.1B and 
3.1F; Fig. 3.2A-C). The knockdown of only BRD4 – and not of BRD2 or BRD3 – 
significantly reduced the expression of Snail and Slug at both the mRNA and protein 
level. Interestingly, E-cadherin expression was significantly increased at the mRNA 
(VCaP and DU 145) and protein level (DU 145) upon BRD4 depletion, yet only 
marginally increased under the same conditions in 22Rv1 cells. We considered the 
possibility that because 22Rv1 cells are characterized as being highly epithelial, 
endogenous E-cadherin expression is already saturated and that the loss of Snail and Slug 
is therefore unable to push these cells into becoming even more epithelial. To address this 
issue and to further determine whether BRD4 regulates this EMT gene signature, we 
overexpressed BRD4 in 22Rv1 and DU 145 cells (Fig. 3.1C and 3.1G). Notably, we 
found that overexpression of BRD4 in each cell line had the opposite effect of knocking 
down BRD4. Loss of BRD4 dramatically increased the expression of Snail and Slug and 
likewise significantly reduced the expression of E-cadherin (Fig. 3.1C and 3.1G; Fig. 
3.3A and 3.3B). These results, coupled with the ChiP-seq data that showed that BRD4 
directly engages at the locus for SNAI1 and SNAI2 (Fig. 3.6), confirmed that only BRD4 
regulates key effectors of EMT in CRPC. 
Selective targeting of BRD4 represses TGFß induced EMT 
In addition to discovering that Snail and Slug are gene targets of BRD4, we also 
showed that the loss of BRD4 uncouples TGFß induced EMT (Fig. 3.4 and Fig. 3.5). 
TGFß is a strong promoter of EMT and metastases in advanced prostate cancer (9,22), 
 
 115 
and works in part by enhancing the expression of Snail and Slug through transcriptional 
activation (9,22). We first confirmed that selective degradation of BRD4 by MZ1 
prevented TGFß from enhancing Snail and Slug expression (Fig. 3.4A and Fig. 3.5A). 
We believe that BRD4 regulates this signaling cascade at the chromatin level, given that 
the loss of BRD4 did not impact Smad3 activation (Fig. 3.4B and Fig. 3.6). This result 
was unexpected given that we had previously showed that BRD4 directly regulates 
AHNAK, and AHNAK has been shown to serve as a necessary scaffolding protein for 
TGFß-Smad3 phosphorylation (23). Therefore, it is likely that AHNAK’s contribution to 
prostate cancer dissemination occurs primarily through its ability to form pseudopodia 
(14). Moreover, we also established that loss of BRD4 enriches E-cadherin expression 
along tight junctions and prevents TGFß-treated prostate cancer cells from losing their 
epithelial morphology (Fig. 3.4C and Fig. 3.5B). This is significant and provides further 
support to our previous findings. We believe that, as BRD4 is lost from the cell, a 
significant number of pro-migratory and EMT transcriptional networks are shutdown. 
This shift reduces the corresponding gene products from being translated into functional 
proteins, which causes the cell to become more epithelial and less capable of generating a 
metastatic phenotype. In support of this interpretation, we also discovered through the 
TCGA database that only BRD4, and not BRD2 or BRD3, correlates with SNAI1 and 
SNAI2 expression in patients with prostate cancer. This relationship proved to be 
translationally significant, as prostate cancer patients with high expression of this BRD4-
regulated EMT gene signature were reported to have a shorter time to biochemical-
recurrence and progression (Fig. 3.7A and 3.7B; Fig 3.8A and 3.8B). Overall, the 
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findings presented throughout (Fig. 2.13 and Fig. 3.9) provide ample evidence that any 
approach that involves targeting the BET proteins as a means for treating mCRPC 
patients should focus on only BRD4, and as briefly discussed in the next subchapter, 
underscores the need for targeted BRD4-selective small molecules to enter clinical trials. 
BET therapies in clinical trials  
As of 2019, 17 different BET inhibitors were in either active phases of clinical trials 
or had reached completion for several different cancers, including six that are being used 
on patients with CRPC/mCRPC (24). Of the six therapies being used in trials that have 
patients with advanced prostate cancer, all are pan-BET inhibiting, including two that are 
being presented as being BRD4-specific (ABBV-744 – BD2 selective towards BRD2, 
BRD3, and BRD4 and PLX51107 – modest preference for BD1 of BRD2, BRD3, and 
BRD4) (24). While it is encouraging to see that some of the early data being reported on 
these inhibitors reflects a relatively tolerable safety profile, it is unfortunately not surprising 
that the efficacy of these inhibitors appears to limited when used as monotherapies due to 
acquired resistance mechanisms (24). These findings once again serve as a painful 
reminder that BET proteins are not always functionally redundant and that pan-BET 
therapies can produce off-target effects, including the reactivation of latent HIV in infected 
T cells (25). As we have shown before on numerous occasions in a variety of cancer 
models, each BET family member regulates transcription in their own unique ways, and 
thus, it remains imperative for the scientific community to first elucidate the relevant BET 
proteins for any specific biological function before rushing therapies into clinical trials 
(11,17,26,27). Lastly, as support for PROTAC based cancer therapies increases (28,29), 
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we feel that BRD4-selective small molecules like MZ1 warrant further exploration as a 
means for treating patients with mCRPC. 
Future directions 
 As I conclude this report, I think it is important to look ahead and to offer my 
opinion as to where our work and field should go from here. Every day our understanding 
of how BET proteins contribute to prostate cancer dissemination improves, and while I 
remain hopeful that our work moves the field forward, I feel it is important that future 
efforts focus on two critical components of the prostate tumor microenvironment: 
immune cells and bone cells. The first component relates to the concept of immune 
evasion, an acquired mechanism by tumor cells that prevents their destruction by 
cytotoxic T cells (CTLs) (30,31). Under normal conditions, CTLs engage and destroy 
tumor cells through numerous receptor-ligand interactions. This process is well 
controlled and involves a series of checkpoints, or “immune checkpoints”, and functions 
to preserve self-tolerance and limit the duration of adaptive immune responses (30,31). 
To overcome destruction by CTLs, tumor cells upregulate certain inhibitory molecules to 
hijack specific immune checkpoints. Programmed Death Ligand 1 or PD-L1, is one 
example of an inhibitory molecule expressed by tumor cells, and works by engaging the 
Programmed Death 1 (PD-1) receptor on CTLs. This engagement activates the PD-1/PD-
L1 axis, and effectively reduces the anti-tumor adaptive responses of CTLs by inducing 
anergy and apoptosis (30,31). Due to the biological significance of immune checkpoints, 
multiple immunotherapies have been developed and have entered clinical trials (32). 
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Although initial findings showed that certain immunotherapies that block the engagement 
of specific receptor-ligand interactions are quite effective for treating patients with 
advanced melanoma (33), the same has not been the case for patients with mCRPC (34). 
While much remains to be learned regarding immune checkpoints, including why these 
therapies have proved to be ineffective more often than not for certain mCRPC patients, 
there is reason to believe that BET proteins play a large role in their activation and 
expression. We have previously shown that BET proteins are required for macrophage 
function and B cell expansion (35,36), and more recently showed that they regulate the 
PD-1/PD-L1 axis in triple negative breast cancer (37). Furthermore, as shown above in 
Fig. 4.1, preliminary experiments suggest that MZ1 is capable of ablating PD-L1 
Figure 4.1. MZ1 ablates PD-L1 expression in DU 145 cells. Flow cytometry 
analysis of DU 145 cells treated with either 0.01% DMSO or 1 µM MZ1 for 48 hours. 
During the last 24 hours, cells were treated with 5 ng/mL of IFNγ. Cells were then 
harvested, stained and run on the FacsCanto to measure PD-L1 expression. The histograms 
represent the quantification of the illustrated flow cytometry curves. Error bars represent 
SEM of two independent experiments. Statistical analyses were performed using a one-way 





expression in DU 145 cells stimulated with IFNγ. Based on these initial results, future 
experiments will need to determine if this phenotype is regulated by an individual BET 
protein, given that these experiments were performed with doses of MZ1 that are not 
selective to BRD4. However, based on this data, it remains possible that 
immunotherapeutic approaches for treating patients with mCRPC could be improved if 
combined with a BET degrader. 
The second component of the prostate tumor microenvironment that I feel 
warrants further exploration is the cross talk that exists between prostate tumor cells and 
bone cells. As mentioned in the previous chapters, over 90% of prostate cancer-
associated mortality is caused by the development of metastases, with a majority 
developing in the bone (9,10,38). While prevailing theories for this process focus on 
signaling events that originate from prostate cancer cells (i.e., AR signaling through 
CXCR4 and through secretion of factors such as TGFß that then reprogram the bone 
niche to support prostate cancer anchorage and growth), prior evidence suggests that 
factors derived from bone stimulate and enhance prostate cancer cell growth and invasion 
(39). Moreover, recent studies have just begun to explore the roles of exosomes or 
extracellular vesicles (EVs) as vehicles for cell-to-cell communication between tumor 
cells and cells in the surrounding environment. EV characterization is typically based on 
biogenesis and size (exosomes are the smallest in size, 30–150 nm), but they can also be 
defined by their molecular content and specific functions (40). While most of the recent 
studies that have explored prostate cancer and bone signaling have focused on exosomes 
derived from tumor cells (41,42), we think this type of cell-to-cell communication is 
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bidirectional, and may even begin with cues generated from bone cells. Furthermore, 
because disruption of the cellular architecture that occurs through the downregulation of 
E-cadherin (a hallmark trait of EMT) is critical for developing bone metastases, it is  
possible that BRD4 regulates this process. To better understand how bone cells, and in 
particular osteocytes, prime prostate tumor cells into becoming more metastatic, we 
treated DU 145 cells with purified exosomes from human primary osteocytes and then 
measured markers of EMT that we had previously shown to be BRD4 regulated (Fig. 
3.1B and 3.1F). As shown below in Fig. 4.2, the setup of for these preliminary 
experiments began by differentiating human primary bone marrow stem cells ex vivo 





into osteocytes, cell culture media was harvested and exosomes were purified (Fig. 4.2A). 
Exosomes were then quantified (characterized by size using NanoSight – Fig. 4.2B) and 
plated with DU 145 cells that were transfected with siRNAs for the BET proteins (cells 
grown in media with exosome-free FBS). Seventy two hours later cells were harvested 
and SNAI1/Snail expression was measured by RT-qPCR and western blot (Fig. 4.2C). 
Critically, we discovered that osteocyte derived exosomes significantly enhanced Snail 
mRNA and protein expression, and that loss of BRD4 ablates this phenomenon.  
Though this finding is preliminary, and likewise, requires a considerable amount 
of additional experiments (identify functionally important differences among exosomes 
based on patient race, age, co-morbidities, characterization of functional exosomes by 
proteomics, functional assays validating proteomic-identified target, transcriptional 
regulation through BET proteins, etc.) the results are compelling. By leveraging the 
findings of our prior work, we have been able to setup an approach that could potentially 
resolve a new mechanism of intercellular communication that is important for prostate 
cancer progression and metastasis. In conclusion, the findings described here and in the 
prior chapters offer new insights into how BET proteins regulate prostate cancer  
Figure 4.2. Human primary osteocyte exosomes, Snail and BRD4. A) Diagram 
showing experiential design and timeline of ex vivo differentiation of human primary MSCs 
into osteoblasts and osteocytes. B) Exosome characterization taken from NanoSight that shows 
size distribution as well as the mean, mode and concentration of sample. C)  mRNA and protein 
expression of SNAI1/Snail in DU 145 cells transfected with BET siRNAs and grown in presence 
of 1x108 exosomes for 72 hours. Error bars represent SEM of two independent experiments. 
Quantifications relative to untreated group with normalization using β-actin levels as a loading 
control are indicated. Statistical analyses were performed using a one-way ANOVA. 





dissemination and provides the scientific community a novel approach for treating 
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